CD19 / CD20 / γδTCR-binding protein and pharmaceutical use thereof

By developing CD19/CD20/γδTCR binding proteins, the problems of tumor target loss and cytokine release syndrome in traditional treatments have been solved, enabling safe multi-target therapy for non-Hodgkin lymphoma, reducing the risk of recurrence and improving treatment efficacy.

WO2026238036A1PCT designated stage Publication Date: 2026-11-19JIANGSU HENGRUI MEDICINE CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096913
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-04-23
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing treatments for non-Hodgkin's lymphoma carry the risk of tumor target loss leading to relapse, and traditional T-cell therapy may trigger severe cytokine release syndrome. There is a lack of safe and effective multi-target treatment options.

Method used

Develop CD19/CD20/γδTCR binding proteins that can specifically bind to CD19 and CD20, activate γδT cells to kill tumor cells, reduce the risk of target loss and reduce the risk of cytokine release syndrome.

Benefits of technology

It provides a safe and effective multi-target therapy for non-Hodgkin's lymphoma, reducing the risk of tumor recurrence and improving the safety and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026096913-FTAPPB-I100001
    Figure PCTCN2026096913-FTAPPB-I100001
  • Figure PCTCN2026096913-FTAPPB-I100002
    Figure PCTCN2026096913-FTAPPB-I100002
  • Figure PCTCN2026096913-FTAPPB-I100003
    Figure PCTCN2026096913-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to a CD19 / CD20 / γδTCR-binding protein and a pharmaceutical use thereof. Specifically, the present invention relates to an anti-CD19 / CD20 / γδTCR trispecific antibody, a method for treating a disease (e.g., a B-cell tumor) using same, and a pharmaceutical use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

CD19 / CD20 / γδTCR binding protein and its medicinal uses

[0001] This disclosure claims priority to Chinese patent applications CN202510616123.6 and CN202610550025.1, which are incorporated herein by reference in their entirety. Technical Field

[0002] This disclosure relates to the biomedical field, specifically to CD19 / CD20 / γδTCR binding proteins, polynucleotides, carriers, combinations or kits, and methods for treating diseases (e.g., B-cell tumors) and related pharmaceutical uses. Background Technology

[0003] Lymphoma is a malignant tumor originating from lymphatic tissue, and the number of new cases worldwide has been increasing in recent years. Data shows that there were as many as 589,600 new cases of lymphoma globally in 2018. Non-Hodgkin lymphoma (NHL) accounts for about 80-90% of lymphomas, and its classification is complex with poor treatment outcomes. Currently, the R-CHOP regimen is commonly used for first- and second-line clinical treatment, namely rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone. This method has cured some NHL cases and prolonged the survival of some NHL patients, but 50% to 60% of patients with aggressive NHL will eventually relapse. The factors causing relapse are not yet clear, but relapsed patients often experience loss of tumor-related targets, and there is currently no standard salvage regimen for relapsed or refractory NHL. Treatment regimens targeting multiple B-cell lymphoma targets can effectively reduce the risk of target loss and help in later-line treatment of lymphoma and prolong patient survival.

[0004] T-cell therapy is a powerful treatment option. CD19 and CD20 are both highly expressed in NHL, and therefore, current clinical drugs such as CD19×CD3 and CD20×CD3 have shown clinical efficacy in treating refractory / relapsed NHL. However, this treatment still carries the risk of relapse due to loss of tumor targets. Therefore, simultaneously targeting multiple B-cell targets, such as CD19 and CD20, can significantly reduce the risk of relapse caused by the loss of a single target.

[0005] γδT cells are immune cells in the human body that can both kill cancer cells and tumor stem cells and recognize cancer antigens. These cells account for 1-10% of PBMCs and play a crucial role in the immune system. Traditional T-cell therapy often overactivates T cells, leading to severe cytokine release syndrome (CRS), posing a significant challenge to the application of this type of drug. In contrast, early clinical data from TAA-γδT dual antibodies, represented by LAVA therapeutics (Front Immunol. 2022 Jun 16; 13:915837), show promising safety and preliminary efficacy. This study found a lower risk of CRS after activating γδT cells, making it safer than traditional T-cell therapy. Due to the lack of MHC restrictions, γδT also has the potential to become a universal cell therapy product, offering a more significant advantage in applicability compared to current CAR-T cell therapies.

[0006] This study aims to develop a more potent CD19 / CD20 / γδT trispecific antibody that can recruit and activate γδT to specifically kill CD19 and CD20 positive tumor cells, exhibiting good tumor-killing activity, safety, and drug-likeness. Summary of the Invention

[0007] This disclosure provides CD19 / CD20 / γδTCR binding proteins, their encoded polynucleotides, their encoded nucleic acids, vectors, host cells, pharmaceutical compositions, combinations or kits, and methods of using them for the treatment or prevention of diseases and related pharmaceutical uses.

[0008] CD19 / CD20 / γδTCR binding protein

[0009] This disclosure provides a binding protein that binds to CD19, CD20, and / or γδTCR. In some embodiments, the CD19 / CD20 / γδTCR binding protein comprises at least one of the following: a γδT cell receptor (γδTCR) binding domain, a CD19 binding domain, and a CD20 binding domain.

[0010] <γδTCR binding domain>

[0011] In some embodiments, the γδTCR binding domain is capable of binding TCR. In some embodiments, it is capable of binding γδTCR. In some embodiments, it is capable of binding the γ9 chain of TCR. In some embodiments, it is capable of binding γ9δ2TCR. In other embodiments, it is capable of binding γ9δ1TCR. In some embodiments, the γδTCR binding domain is a TRGV9 binding domain.

[0012] In some embodiments, the γδTCR binding domain comprises: an immunoglobulin single variable domain; the immunoglobulin single variable domain comprises CDR1, CDR2 and / or CDR3 in any of the amino acid sequences shown in SEQ ID NO:28, 61, 69-71, for example, the immunoglobulin single variable domain comprises CDR3 in any of the amino acid sequences shown in SEQ ID NO:28, 61, 69-71.

[0013] In some implementations, the CDR is defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system, for example, according to the Kabat numbering system.

[0014] In some embodiments, a γδTCR binding domain is provided, comprising: an immunoglobulin single variable domain comprising CDR1, CDR2 and / or CDR3, wherein CDR1 comprises the amino acid sequence shown in SEQ ID NO: 13, CDR2 comprises the amino acid sequence shown in SEQ ID NO: 14, and CDR3 comprises the amino acid sequence shown in SEQ ID NO: 15.

[0015] In some embodiments, a γδTCR binding domain is provided, comprising an immunoglobulin single variable domain comprising CDR1, CDR2, and CDR3, respectively, as shown in SEQ ID NO: 13-15.

[0016] In some implementations, the aforementioned immunoglobulin single variable domain is humanized, reversed mutation, affinity maturation, or T cell epitope removal / reduction (TCE).

[0017] In some implementations, the heavy chain framework region of the human lineage template used for the aforementioned humanization of a single variable domain of immunoglobulin is derived from IGHV3-30.

[0018] In some embodiments, a γδTCR binding domain is provided, comprising: an immunoglobulin single variable domain, said immunoglobulin single variable domain comprising an amino acid sequence as shown in any one of SEQ ID NO:28, 61, 69-71 or having at least 80% or at least 90% identity with it.

[0019] In this disclosure, "at least 80% (sequence) identity" encompasses at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% (sequence) identity; "at least 90% (sequence) identity" encompasses at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% (sequence) identity.

[0020] In some implementations, the aforementioned γδTCR binding domain may contain one or more (e.g., 2, 3, 4, 5, 6, 7, 8, etc.) of the aforementioned immunoglobulin single variable domains.

[0021] In some embodiments, the aforementioned γδTCR binding protein comprises or is an anti-γδTCR antibody or its antigen-binding fragment. In some embodiments, the anti-γδTCR antibody or its antigen-binding fragment is a recombinant antibody or a fragment thereof. In some embodiments, the anti-γδTCR antibody is a monospecific antibody, a bispecific antibody, or a multispecific antibody (e.g., a trispecific antibody).

[0022] In some embodiments, when the γδTCR binding domain contains a single variable domain of an immunoglobulin, it can be a camel antibody, chimeric antibody, humanized antibody, fully human antibody, or its antigen-binding fragment. For example, the single variable domain of the immunoglobulin is a single-domain antibody or a VHH. As an example, the aforementioned γδTCR binding domain itself is a single-domain antibody or a VHH. In some specific embodiments, the antibody or its antigen-binding fragment is a linear antibody, a single-chain antibody, a nanobody, a peptide antibody (peptibody), a domain antibody and a diabody, a triabody and a tetrabody, a tandem di-scFv, or a tandem tri-scFv.

[0023] In some embodiments, the aforementioned γδTCR binding domain is: a protein that specifically binds to γδTCR, or an anti-γδTCR antibody or its antigen-binding fragment; a protein that specifically binds to the γ9 chain of TCR, or an anti-γ9 chain of TCR or its antigen-binding fragment; a protein that specifically binds to the variable region (Vγ9) of the γ9 chain of TCR, or an anti-Vγ9TCR antibody or its antigen-binding fragment; a protein that specifically binds to γ9δ2TCR, or an anti-γ9δ2TCR antibody or its antigen-binding fragment; a protein that specifically binds to γ9δ1TCR, or an anti-γ9δ1TCR antibody or its antigen-binding fragment; or a protein that specifically binds to TRGV9, or an anti-TRGV9 antibody or its antigen-binding fragment.

[0024] In some implementations, the aforementioned γδTCR binding domain has a function or property selected from at least one of the following:

[0025] (a) γ9δ2T cells are bound with EC50 at a concentration of ≤10 nM, wherein the EC50 is, for example, ≤5 nM, ≤4 nM, ≤3 nM, ≤2 nM, ≤1 nM, ≤0.5 nM, ≤0.2 nM, or ≤0.1 nM. The EC50 is obtained by FACS detection, which is a commonly used affinity detection method in the art, such as that described in Example 7 of this disclosure.

[0026] (b) Specifically binds to the γ9 chain of TCR, for example, specifically binds to γ9δ1TCR and γ9δ2TCR;

[0027] (c) γ8 chains that do not bind to TCR (cannot be detected by testing methods), for example, those that do not bind to γ8δ2TCR;

[0028] (d) The variable region (TRGV9) of the γ9 chain that specifically binds to TCR;

[0029] (e) Specifically binds to VγδCαβ chimeric TCRs, but does not bind to VαβCγδ chimeric TCRs;

[0030] (f) Binding to cynomolgus monkey γ9δ2TCR;

[0031] Wherein, (b)-(e) can be obtained by conventional detection methods in the art, such as those described in Embodiment 4 of this disclosure.

[0032] In some implementations, the KD value of the aforementioned γδTCR binding domain binding TRGV9 can be ≤1×10-7M, for example ≤1×10-8M, or ≤1×10-9M, or ≤1×10-10M.

[0033] In some embodiments, the aforementioned γδ TCR binding domain encompasses a variant of a single immunoglobulin variable domain, which has one or more amino acid mutations compared to any of SEQ ID NO: 28, 61, 69-71. "Plurality" encompasses 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. The amino acid mutations may be conservative substitutions, replacements or modifications, and / or deletions or additions that do not affect the function; the amino acid mutations may occur in the CDR region and / or the FR region.

[0034] In some embodiments, a γδ TCR binding domain is provided, which binds to the same epitope as the single immunoglobulin variable domain in the aforementioned γδ TCR binding domain of the present disclosure. In some embodiments, a protein is provided, which competes for binding with the immunoglobulin variable domain of the aforementioned γδ TCR binding domain of the present disclosure.

[0035] In some embodiments, a γδ TCR binding domain is provided, whose binding to TRGV9 is blocked by the single immunoglobulin variable domain in the aforementioned γδ TCR binding domain of the present disclosure.

[0036] <CD19 binding domain>

[0037] In some embodiments, the CD19 binding domain comprises a heavy chain variable region (VH1) and a light chain variable region (VL1).

[0038] In some embodiments, the VH1 comprises HCDR1, HCDR2 and HCDR3 in the amino acid sequence set forth in SEQ ID NO:22, and / or the VL1 comprises LCDR1, LCDR2 and LCDR3 in the amino acid sequence set forth in SEQ ID NO:23.

[0039] In some embodiments, the CDRs are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system, for example, according to the Kabat numbering system.

[0040] In some embodiments, the CD19 binding domain comprises: HCDR1, HCDR2, HCDR3 as set forth in SEQ ID NOs:1-3 respectively, and LCDR1, LCDR2, LCDR3 as set forth in SEQ ID NOs:4-6 respectively;

[0041] In some embodiments, the CD19 binding domain comprises a combination of at least 1, at least 2, at least 3, at least 4, at least 5 or 6 of the aforementioned HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3.

[0042] In some embodiments, the CD19 binding domain contains HCDR1 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned HCDR1; and / or, it contains HCDR2 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned HCDR2; and / or, it contains HCDR3 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned HCDR3; and / or, it contains LCDR1 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned LCDR1; and / or, it contains LCDR2 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned LCDR2; and / or, it contains LCDR3 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned LCDR3. In some specific embodiments, the amino acid mutations are conserved substitutions.

[0043] In some embodiments, the CD19 binding domain is a fully human antibody, a chimeric antibody, a humanized antibody, or an antigen-binding fragment. In some embodiments, the antibody is a recombinant antibody or an antigen-binding fragment. In some embodiments, the antibody is a monospecific antibody or a multispecific antibody (e.g., a bispecific antibody, a trispecific antibody, a tetraspecific antibody, etc.), or an antigen-binding fragment.

[0044] In some implementations, the CD19 binding domain includes, but is not limited to: scFv, Fab, Fv, sFv, Fab', F(ab')2, linear antibody, single-chain antibody, sdAb, sdFv, nanobody, peptide antibody, domain antibody, diabody, triabody and tetrabody, tandem di-scFv, and tandem tri-scFv.

[0045] In some implementations, the aforementioned CD19 binding domain is humanized, reverted to mutation, or removed / reduced T cell epitopes (TCEs).

[0046] In some implementations, the CD19 binding domain includes VH1 and VL1, wherein:

[0047] The VH1 contains an amino acid sequence as shown in SEQ ID NO:22 or having at least 80% or at least 90% identity with it, and the VL1 contains an amino acid sequence as shown in SEQ ID NO:23 or having at least 80% or at least 90% identity with it.

[0048] In some implementations, the CD19 binding domain comprises any one or any two of the aforementioned VH and VL.

[0049] In some embodiments, the CD19 binding domain comprises any CD19-binding CDR, VH / VL, or LC / HC sequence disclosed in WO2009052431. The aforementioned patent is hereby incorporated by reference in its entirety into the present disclosure.

[0050] In some embodiments, a CD19 binding domain is provided, which binds to the same epitope as the CD19 binding domain of the aforementioned present disclosure. In some embodiments, a protein is provided, which competes for binding with the CD19 binding domain of the aforementioned present disclosure.

[0051] In some embodiments, a CD19 binding domain is provided, whose binding to CD19 is blocked by the CD19 binding domain of the aforementioned present disclosure.

[0052] <CD20 binding domain>

[0053] In some embodiments, the CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2).

[0054] In some embodiments, the VH2 comprises HCDR1, HCDR2 and HCDR3 in the amino acid sequence set forth in SEQ ID NO:24, and / or the VL2 comprises LCDR1, LCDR2 and LCDR3 in the amino acid sequence set forth in SEQ ID NO:25.

[0055] In some embodiments, the VH2 comprises HCDR1, HCDR2 and HCDR3 in the amino acid sequence set forth in SEQ ID NO:26, and / or the VL2 comprises LCDR1, LCDR2 and LCDR3 in the amino acid sequence set forth in SEQ ID NO:27.

[0056] In some embodiments, the CDRs are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system, for example, defined according to the Kabat numbering system.

[0057] In some embodiments, the CD20 binding domain comprises: HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NO:7-9 respectively, and LCDR1, LCDR2 and LCDR3 as set forth in SEQ ID NO:10-12 respectively.

[0058] In some embodiments, the CD20 binding domain comprises: HCDR1, HCDR2 and HCDR3 as set forth in SEQ ID NO:16-18 respectively, and LCDR1, LCDR2 and LCDR3 as set forth in SEQ ID NO:19-21 respectively.

[0059] In some implementations, the CD20 binding domain includes a combination of at least one, at least two, at least three, at least four, at least five, or at least six of the aforementioned HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3.

[0060] In some embodiments, the CD20 binding domain contains HCDR1 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned HCDR1; and / or, it contains HCDR2 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned HCDR2; and / or, it contains HCDR3 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned HCDR3; and / or, it contains LCDR1 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned LCDR1; and / or, it contains LCDR2 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned LCDR2; and / or, it contains LCDR3 with 1, 2, 3, 4, 5, or 6 amino acid mutations compared to any of the aforementioned LCDR3. In some specific embodiments, the amino acid mutations are conserved substitutions.

[0061] In some embodiments, the CD20 binding domain is a fully human antibody, a chimeric antibody, a humanized antibody, or an antigen-binding fragment. In some embodiments, the antibody is a recombinant antibody or an antigen-binding fragment. In some embodiments, the antibody is a monospecific antibody or a multispecific antibody (e.g., a bispecific antibody, a trispecific antibody, a tetraspecific antibody, etc.), or an antigen-binding fragment.

[0062] In some implementations, the CD20 binding domain includes, but is not limited to: scFv, Fab, Fv, sFv, Fab', F(ab')2, linear antibody, single-chain antibody, sdAb, sdFv, nanobody, peptide antibody, domain antibody, diabody, triabody and tetrabody, tandem di-scFv, and tandem tri-scFv.

[0063] In some implementations, the aforementioned CD20 binding domain is humanized, reversed mutation, or removed / reduced T cell epitope (TCE).

[0064] In some embodiments, the CD20 binding domain comprises VH2 and VL2, wherein: the VH2 comprises the amino acid sequence set forth in SEQ ID NO:24 or an amino acid sequence having at least 80%, or at least 90% identity thereto, and the VL2 comprises the amino acid sequence set forth in SEQ ID NO:25 or an amino acid sequence having at least 80%, or at least 90% identity thereto.

[0065] In some embodiments, the CD20 binding domain comprises VH2 and VL2, wherein: the VH2 comprises the amino acid sequence set forth in SEQ ID NO:26 or an amino acid sequence having at least 80%, or at least 90% identity thereto, and the VL2 comprises the amino acid sequence set forth in SEQ ID NO:27 or an amino acid sequence having at least 80%, or at least 90% identity thereto.

[0066] In some embodiments, the CD20 binding domain comprises any one or a combination of any two of the aforementioned VH and VL.

[0067] In some embodiments, the CD20 binding domain comprises any CD20-binding CDR, VH / VL, or LC / HC sequence disclosed in WO2004035607. The aforementioned patent is incorporated herein by reference in its entirety.

[0068] In some embodiments, a CD20 binding domain is provided that binds to the same epitope as the aforementioned CD20 binding domains of the present disclosure. In some embodiments, a protein is provided that competes for binding with the aforementioned CD20 binding domains of the present disclosure.

[0069] In some embodiments, a CD20 binding domain is provided whose binding to CD20 is blocked by the aforementioned CD20 binding domains of the present disclosure.

[0070] <Fc region>

[0071] In some embodiments, the aforementioned CD19 / CD20 / γδTCR binding protein further comprises a human immunoglobulin Fc region; for example, the Fc region is an Fc region derived from human IgG1, IgG2, IgG3 or IgG4. In some embodiments, the Fc region is an engineered Fc region that comprises modifications that alter one or more properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and / or effector functions (e.g., antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP)).

[0072] In some embodiments, the Fc region is an Fc region with reduced effector function, such as an Fc region with reduced antibody-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) function compared to human IgG1; in other embodiments, the Fc region has reduced antibody-dependent cell-mediated cytotoxicity (ADCC) function and / or reduced complement-dependent cytotoxicity (CDC) compared to human IgG1. In other embodiments, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to change the effector function of the antibody or antigen-binding fragment. For example, one or more amino acids selected from amino acid residues 234, 235, 236, 237, 265, 297, 318, 320, and 322 can be replaced with different amino acid residues, such that the antibody has altered affinity for the effector ligand while retaining the antigen-binding ability of the parent antibody.

[0073] In some embodiments, the Fc region is the Fc region of human IgG1. In some specific embodiments, the Fc region may be an Fc region with reduced effector function; for example, the Fc region may have a mutation. Exemplary IgG Fc regions with reduced effector function include those with the following substitutions: N297A or N297Q (IgG1); L234A / L235A (IgG1); D265S (IgG1); L234F / L235E (IgG1); L234F / L235E / D265S (IgG1); L234A / L235A / D265S (IgG1); V234A / G237A (IgG2); L235A / G237A / E318A (IgG4); H268Q / V309L / A330S / A331S (IgG2); C220S / C226S / C229S / P238S (IgG1); C226S / C229S / E233P / L234V / L235A (IgG1); L234F / L235E / P331S (IgG1); L234F / L235E (IgG1); L234F or L235E (IgG1); L234A or L235A (IgG1) or S267E / L328F (IgG1). For example, L234A / L235A indicates a sequence containing both L234A and L235A. In some implementations, Fc region mutations are defined according to the EU numbering system.

[0074] In some embodiments, the Fc comprises at least one human IgG1 as shown below: L234A or L234F, L235A or L235E, D265S. In some embodiments, the Fc comprises L234F / L235E, L234F / L235E / D265S, L234A / L235A / D265S, or L234A / L235A.

[0075] In some specific embodiments, the Fc region comprises a first subunit (Fc1) and a second subunit (Fc2). In some specific embodiments, mutations are introduced that cause the two subunits (Fc1, Fc2) of the Fc region to pair and form a dimer, or mutations that reduce homodimerization are introduced. In some specific embodiments, the first and second subunits contain knock-in-hole mutations. For example, within the CH3 / CH3 interface, one, two, or more amino acid residues in the CH3 domain of Fc2 are mutated to one or more amino acid residues with a larger side chain volume, thereby creating a protrusion (or pestle, knob) on the surface of the CH3 domain of Fc2. Correspondingly, one, two, or more amino acid residues in the CH3 domain of Fc1 that interact with the CH3 domain of Fc2 are mutated to amino acid residues with a smaller side chain volume, thereby creating a depression (or hole, hole) on the surface of the CH3 domain of Fc1. The first subunit (Fc1) and the second subunit (Fc2) are interchangeable only to distinguish the two different subunits.

[0076] In some specific embodiments, Fc2 contains one or more amino acid substitutions selected from positions 354, 356, 358, and 366, and Fc1 contains one or more amino acid substitutions selected from positions 349, 356, 358, 366, 368, and 407. In some specific embodiments, Fc2 contains a mutation at position 366, and Fc1 contains a mutation selected from positions 366, 368, and 407, or any combination thereof. In some specific embodiments, Fc2 contains a mutation at position 354 or 356, and Fc1 contains a mutation at position 349. In some specific embodiments, Fc2 contains a mutation at position 354 or 356, and Fc1 contains mutations at positions 349, 366, 368, and 407.

[0077] In some specific embodiments, Fc2 contains one or more amino acid substitutions selected from 354C, 356E, 358M, and 366W, and Fc1 contains one or more amino acid substitutions selected from 349C, 356E, 358M, 366S, 368A, and 407V. In some specific embodiments, Fc2 contains a 366W mutation, and Fc1 contains a mutation selected from 366S, 368A, and 407V, or any combination thereof. In some specific embodiments, Fc2 contains a 354C or 356C mutation, and Fc1 contains a 349C mutation. Or in some specific embodiments, Fc2 contains a 354C / 366W mutation, and Fc1 contains a 349C / 366S / 368A / 407V mutation.

[0078] In some specific embodiments, Fc2 contains the T366W mutation, and Fc1 contains a mutation selected from T366S, L368A, and Y407V, or any combination thereof; Fc2 contains the S354C or E356C mutation, and Fc1 contains the Y349C mutation; or Fc2 contains the S354C / T366W mutation, and Fc1 contains the Y349C / T366S / L368A / Y407V mutation. In some specific embodiments, Fc2 comprises an amino acid sequence as shown in SEQ ID NO: 40 or having at least 80% or at least 90% identity with it, and Fc1 comprises an amino acid sequence as shown in SEQ ID NO: 39 or having at least 80% or at least 90% identity with it. In some specific embodiments, Fc2 contains an amino acid sequence as shown in SEQ ID NO: 75 or having at least 80% or at least 90% identity with it, and Fc1 contains an amino acid sequence as shown in SEQ ID NO: 74 or having at least 80% or at least 90% identity with it.

[0079] In some specific embodiments, Fc1 contains the T366W mutation, and Fc2 contains a mutation selected from T366S, L368A, and Y407V, or any combination thereof; Fc1 contains the S354C or E356C mutation, and Fc2 contains the Y349C mutation; or Fc1 contains the S354C / T366W mutation, and Fc2 contains the Y349C / T366S / L368A / Y407V mutation. In some specific embodiments, Fc1 comprises an amino acid sequence as shown in SEQ ID NO: 40 or having at least 80% or at least 90% identity with it, and Fc2 comprises an amino acid sequence as shown in SEQ ID NO: 39 or having at least 80% or at least 90% identity with it. In some specific embodiments, Fc1 contains an amino acid sequence as shown in SEQ ID NO: 75 or having at least 80% or at least 90% identity with it, and Fc2 contains an amino acid sequence as shown in SEQ ID NO: 74 or having at least 80% or at least 90% identity with it.

[0080] In some implementations, the aforementioned CD19 / CD20 / γδTCR binding protein contains amino acid size and charge mutations at the heavy chain CH1 and light chain CL interface, which reduces mismatches between the heavy and light chains. For example, Roche swapped the CH1 and CL domains and created the CrossMab platform (Schaefer et al., Proceedings of the National Academy of Sciences of the United States of America, 108(27), pp.11187–11192(2011)), MedImmune mutant heavy chain F126C and light chain S121C introduced disulfide bonds (Mazor et al., mAbs, 7(2), pp.377–389(2015)), Amgen further modified the CH1-CL region with electrostatic interactions (Liu et al., Journal of Biological Chemistry, 290(12), pp.7535–7562(2015)), and Lilly (Lewis et al., Nature Biotechnology, 32(2), pp.191–198 (2014) and Genentech (Dillon et al., mAbs, 9(2), pp.213–230 (2017)) introduced mutations in both the variable and constant domains. WuXi AppTec replaced the constant region of the antibody with the constant region of the TCR, as described in CN109535257A (cited and incorporated in full).

[0081] In some embodiments, the aforementioned CD19 / CD20 / γδTCR binding protein comprises an Obscurin-O chain and a Titin-T chain to prevent or reduce mismatches between different VH and VL. The Obscurin-O chain and the Titin-T chain are described in patent WO2021139758A, which is incorporated herein by reference in its entirety.

[0082] In some implementations, the aforementioned CD19 / CD20 / γδTCR binding protein includes a linker.

[0083] In some embodiments, the immunoglobulin single variable domain or VH, VL in the aforementioned CD19 / CD20 / γδTCR binding protein is directly or indirectly linked to the Fc region via a linker. In some embodiments, the immunoglobulin single variable domain or VH, VL in the aforementioned CD19 / CD20 / γδTCR binding protein is directly or indirectly linked to the Obscurin-O chain or Titin-T chain via a linker. In some embodiments, the immunoglobulin single variable domain in the aforementioned CD19 / CD20 / γδTCR binding protein is directly or indirectly linked to VH or VL via a linker. The linker can be a non-functional amino acid sequence of 1-20 or more amino acids in length, without secondary or higher structures. For example, the linker is such as (G... m S n ) h or (G) m Q n ) h Or (GGNGT) h (SEQ ID NO:81) or (YGNGT) h (SEQ ID NO:82) or (EPKSS) h (SEQ ID NO:83) or (A) m S n ) h As shown, m and n are each independently selected from integers 1-8, and h is independently selected from integers 1-20. For example, the connector is selected from G4S (SEQ ID NO:53), GS, GAP, (G4S)2 (SEQ ID NO:54), (G4S)3 (SEQ ID NO:76), (G4S)4 (SEQ ID NO:77), (G4S)5 (SEQ ID NO:78), ASGS (SEQ ID NO:79), A3S (SEQ ID NO:80), etc.

[0084] In some implementations, the CD19 / CD20 / γδTCR binding protein comprises a first heavy chain, a first light chain, a second heavy chain, and a second light chain, wherein:

[0085] (1) The first heavy chain includes [VH1]-[connector 1]-[CH1]-[connector 2]-[Fc1],

[0086] The first light chain includes [VL1]-[connector 3]-[CL],

[0087] The second heavy chain includes [immunoglobulin variable domain]-[linker 4]-[VH2]-[linker 5]-[CH1]-[linker 6]-[Fc2],

[0088] The second light chain includes [VL2]-[connector 7]-[CL];

[0089] or,

[0090] (2) The first heavy chain includes [VH1]-[connector 1]-[CH1]-[connector 2]-[Fc2],

[0091] The first light chain includes [VL1]-[connector 3]-[CL],

[0092] The second heavy chain includes [immunoglobulin variable domain]-[linker 4]-[VH2]-[linker 5]-[CH1]-[linker 6]-[Fc1],

[0093] The second light chain includes [VL2]-[connector 7]-[CL];

[0094] or,

[0095] (3) The first heavy chain includes [VH1]-[connector 8]-[Obscurin-O chain]-[connector 9]-[Fc1],

[0096] The first light chain includes [VL1]-[connector 10]-[Titin-T chain],

[0097] The second heavy chain includes [immunoglobulin variable domain]-[linker 11]-[VH2]-[linker 12]-[CH1]-[linker 13]-[Fc2],

[0098] The second light chain includes [VL2]-[connector 14]-[CL];

[0099] or,

[0100] (4) The first heavy chain includes [VH1]-[connector 8]-[Obscurin-O chain]-[connector 9]-[Fc2],

[0101] The first light chain includes [VL1]-[connector 10]-[Titin-T chain],

[0102] The second heavy chain includes [immunoglobulin variable domain]-[linker 11]-[VH2]-[linker 12]-[CH1]-[linker 13]-[Fc1].

[0103] The second light chain comprises [VL2]-[connector 14]-[CL].

[0104] In some embodiments, VH1 and VL1 are selected from the aforementioned CD19 binding domain; in some embodiments, VH2 and VL2 are selected from the aforementioned CD20 binding domain; in some embodiments, the immunoglobulin variable domain is selected from the aforementioned γδTCR binding domain.

[0105] In some implementations, connectors 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 may be the same or different, may exist independently or not, and may be selected independently from the connectors mentioned above in this disclosure.

[0106] In some implementations, connectors 1, 2, and 3 are not present; connector 4 is GGGGSGGGGS (SEQ ID NO:77) or GGGGS (SEQ ID NO:76); and connectors 5, 6, and 7 are not present.

[0107] In some implementations, connectors 8 and 10 are G4S or (G4S)2, connector 11 is G4S or (G4S)2, and connectors 9, 12, 13, and 14 are not present.

[0108] In some implementations, connectors 8 and 10 are G4S, connector 11 is (G4S)2, and connectors 9, 12, 13, and 14 are not present.

[0109] In some specific embodiments, the Obscurin-O chain comprises an amino acid sequence as shown in SEQ ID NO:29 or having at least 80% or at least 90% identity with it.

[0110] In some specific embodiments, the Titin-T chain comprises an amino acid sequence as shown in SEQ ID NO:30 or having at least 80% or at least 90% identity with it.

[0111] In some specific embodiments, CH1 contains an amino acid sequence as shown in SEQ ID NO:31 or having at least 80% or at least 90% identity with it.

[0112] In some specific embodiments, the CL is Cκ; in some embodiments, the CL contains an amino acid sequence as shown in SEQ ID NO:32 or having at least 80% or at least 90% identity with it.

[0113] In some embodiments, Fc1 comprises an amino acid sequence as shown in or having at least 80% or 90% identity with SEQ ID NO:39 or 74, and Fc2 comprises an amino acid sequence as shown in or having at least 80% or 90% identity with SEQ ID NO:40 or 75.

[0114] In some specific embodiments, Fc1 contains an amino acid sequence as shown in SEQ ID NO:39 or having at least 80% or at least 90% identity with it, and Fc2 contains an amino acid sequence as shown in SEQ ID NO:40 or having at least 80% or at least 90% identity with it; or, Fc1 contains an amino acid sequence as shown in SEQ ID NO:74 or having at least 80% or at least 90% identity with it, and Fc2 contains an amino acid sequence as shown in SEQ ID NO:75 or having at least 80% or at least 90% identity with it.

[0115] In some embodiments, the CD19 / CD20 / γδTCR binding protein comprises a first heavy chain, a first light chain, a second heavy chain, and a second light chain, wherein:

[0116] (1) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:33 or having at least 80% or at least 90% identity with it.

[0117] The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80% or at least 90% identity with it.

[0118] The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:35 or having at least 80% or at least 90% identity with it.

[0119] The second light chain comprises an amino acid sequence as shown in SEQ ID NO:36 or having at least 80% or at least 90% identity with it;

[0120] or,

[0121] (2) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:33 or having at least 80% or at least 90% identity with it.

[0122] The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80% or at least 90% identity with it.

[0123] The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:37 or having at least 80% or at least 90% identity with it.

[0124] The second light chain comprises an amino acid sequence as shown in SEQ ID NO:38 or having at least 80% or at least 90% identity with it;

[0125] or,

[0126] (3) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:55 or having at least 80% or at least 90% identity with it.

[0127] The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80% or at least 90% identity with it.

[0128] The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:56 or having at least 80% or at least 90% identity with it.

[0129] The second light chain comprises an amino acid sequence as shown in SEQ ID NO:38 or having at least 80% or at least 90% identity with it.

[0130] In some embodiments, the aforementioned CD19 / CD20 / γδTCR binding protein is an anti-CD19 / CD20 / γδTCR antibody or its antigen-binding fragment. In some embodiments, the CD19 / CD20 / γδTCR binding protein is an anti-CD19 / CD20 / γδTCR trispecific antibody or its antigen-binding fragment.

[0131] In some embodiments, the aforementioned CD19 / CD20 / γδTCR binding protein has a function or property selected from at least one of the following:

[0132] (a) γ9δ2T cells are bound with EC50 at a concentration of ≤10 nM, wherein the EC50 is, for example, ≤5 nM, ≤4 nM, ≤3 nM, ≤2 nM, ≤1 nM, ≤0.5 nM, ≤0.2 nM, or ≤0.1 nM. The EC50 is obtained by FACS detection, a commonly used affinity detection method in the art, such as that described in Example 7 of this disclosure.

[0133] (b) Specifically binds to the γ9 chain of TCR, for example, specifically binds to γ9δ1TCR, specifically binds to γ9δ2TCR;

[0134] (c) γ8 chains that do not bind TCR, for example, those that do not bind γ8δ2TCR;

[0135] (d) The variable region (TRGV9) of the γ9 chain that specifically binds to TCR;

[0136] (e) Specifically binds to VγδCαβ chimeric TCRs, but does not bind to VαβCγδ chimeric TCRs;

[0137] Wherein, (b)-(e) can be obtained by conventional detection methods in the art, such as those described in Embodiment 4 of this disclosure;

[0138] (f) Specifically binds to CD19 and / or CD20 proteins, or CD19 and / or CD20 positive cells, and does not bind or hardly binds to CD19 and / or CD20 negative cells, for example, using the detection method of Example 8 of this disclosure;

[0139] (g) Binds to cynomolgus monkey CD19, CD20 and γ9δ2 proteins;

[0140] (i) Mediating the killing of CD19 and / or CD20-positive tumor cells by γδT cells or mediating the killing of CD19 and / or CD20-positive tumor cells by γδT cells in a CD19 and / or CD20 expression level-dependent manner; and / or, mediating the killing of CD19 and / or CD20-positive tumor cells by γδT cells in an effector-to-target ratio-dependent manner; and / or, mediating the killing of CD19 and / or CD20-positive tumor cells by γδT cells in a manner with low individual variability; the killing detection method may use methods known in the art, such as the detection method of Example 10 of this disclosure;

[0141] (j) During the killing of CD19 and / or CD20 positive tumor cells by γδT cells, less cytokine (such as IFNγ, TNFα) is induced.

[0142] (k) Promotes the proliferation of γδT cells in PBMCs;

[0143] (l) In vivo inhibition of CD19 and / or CD20 positive tumor cell proliferation, and / or inhibition of CD19 and / or CD20 positive tumor growth, and / or elimination of CD19 and / or CD20 positive tumors;

[0144] In some implementations, the KD value of the aforementioned CD19 / CD20 / γδTCR binding protein to TRGV9 can be ≤1×10-7M, for example ≤1×10-8M, or ≤1×10-9M, or ≤1×10-10M.

[0145] In some implementations, the KD value of the aforementioned CD19 / CD20 / γδTCR binding protein to CD19 can be ≤1×10-7M, for example ≤1×10-8M, or ≤1×10-9M, or ≤1×10-10M.

[0146] In some implementations, the KD value of the aforementioned CD19 / CD20 / γδTCR binding protein to CD20 can be ≤1×10-7M, for example ≤1×10-8M, or ≤1×10-9M, or ≤1×10-10M.

[0147] In some embodiments, a protein is provided that binds to or competitively binds to the same TRGV9, CD19, and / or CD20 epitopes as described above with the CD19 / CD20 / γδTCR binding protein of this disclosure.

[0148] In some embodiments, a protein is provided whose binding to TRGV9, CD19, and / or CD20 is blocked by the aforementioned CD19 / CD20 / γδTCR binding protein of this disclosure.

[0149] In some embodiments, the CD19 / CD20 / γδTCR binding protein is a conjugate or fusion protein, which may, for example, contain any detectable label or drug molecule. Exemplarily, the drug molecule is, for example, a chemotherapeutic agent or drug, a growth inhibitor, a protein, a peptide, a toxin (e.g., a bacterial, fungal, plant, or animal-derived protein toxin, an enzymatically active toxin, or a fragment thereof), or a radioisotope.

[0150] Polynucleotides and carriers

[0151] This disclosure provides a polynucleotide encoding the CD19 / CD20 / γδTCR binding protein of this disclosure. The nucleic acid of this disclosure may be RNA, DNA, or cDNA. According to some embodiments of this disclosure, the nucleic acid of this disclosure is a substantially isolated nucleic acid.

[0152] The nucleic acids disclosed herein may also be in vector form, may be present in a vector and / or may be part of a vector, such as a plasmid, sticky-terminal plasmid, YAC, or viral vector. The vector may be, in particular, an expression vector, providing a means of expressing CD19 / CD20 / γδTCR binding proteins in vitro and / or in vivo (i.e., in a suitable host cell, host organism, and / or expression system). This expression vector typically contains at least one nucleic acid of this disclosure, operably linked to one or more suitable expression regulatory elements (e.g., promoters, enhancers, terminators, etc.). Selection of these elements and their sequences for expression in a particular host is common knowledge to those skilled in the art. Regulatory elements and other elements useful or necessary for the expression of the CD19 / CD20 / γδTCR binding proteins of this disclosure include, for example, promoters, enhancers, terminators, integrators, selection markers, leader sequences, and reporter genes.

[0153] The nucleic acids disclosed herein can be prepared or obtained by known means (e.g., by automated DNA synthesis and / or recombinant DNA technology) based on information about the amino acid sequence of the polypeptides disclosed herein, and / or can be isolated from suitable natural sources.

[0154] In some implementations, a polynucleotide is provided that encodes a CD19 / CD20 / γδTCR binding protein comprising a γδT cell receptor (γδTCR) binding domain, a CD19 binding domain, and a CD20 binding domain.

[0155] In some implementations, the γδTCR binding domain comprises:

[0156] 1) CDR1, CDR2, and CDR3 in any of the amino acid sequences shown in SEQ ID NO:28, 61, 69-71;

[0157] 2) CDR1, CDR2, and CDR3 of the amino acid sequences shown in SEQ ID NO:13, 14, and 15;

[0158] The CDR is defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system, for example, it is defined according to the Kabat numbering system.

[0159] In some embodiments, the γδTCR binding domain comprises an amino acid sequence comprising or having at least 80% or at least 90% identity with any one of 28, 61, 69-71.

[0160] In some implementations, the CD19 binding domain comprises a heavy chain variable region (VH1) and a light chain variable region (VL1), wherein:

[0161] The VH contains HCDR1, HCDR2 and HCDR3 in the amino acid sequence shown in SEQ ID NO:22, and the VL contains LCDR1, LCDR2 and LCDR3 in the amino acid sequence shown in SEQ ID NO:23.

[0162] or,

[0163] The VH1 contains HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO:1-3, and the VL1 contains LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO:4-6.

[0164] CDR1, CDR2, and CDR3 are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system.

[0165] In some embodiments, the CD19 binding domain comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

[0166] The VH1 contains an amino acid sequence as shown in SEQ ID NO:22 or having at least 80% or at least 90% identity with it, and the VL1 contains an amino acid sequence as shown in SEQ ID NO:23 or having at least 80% or at least 90% identity with it.

[0167] In some implementations, the CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein:

[0168] The VH2 comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:24, and the VL2 comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:25; or,

[0169] The VH2 contains HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO:7-9, and the VL2 contains LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO:10-12.

[0170] The CDR is defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system.

[0171] In some implementations, the CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein:

[0172] The VH2 contains HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:26, and the VL2 contains LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:27; or,

[0173] The VH2 contains HCDR1, HCDR2 and HCDR3 with the amino acid sequences shown in SEQ ID NO:16-18, and the VL2 contains LCDR1, LCDR2 and LCDR3 with the amino acid sequences shown in SEQ ID NO:19-21.

[0174] The CDR is defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system.

[0175] In some embodiments, the CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein:

[0176] The VH2 contains an amino acid sequence as shown in SEQ ID NO:24 or having at least 80% or at least 90% identity with it, and the VL2 contains an amino acid sequence as shown in SEQ ID NO:25 or having at least 80% or at least 90% identity with it.

[0177] In some embodiments, the CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein:

[0178] The VH2 comprises an amino acid sequence as shown in SEQ ID NO:26 or having at least 80% or at least 90% identity with it, and the VL2 comprises an amino acid sequence as shown in SEQ ID NO:27 or having at least 80% or at least 90% identity with it.

[0179] In some embodiments, the CD19 / CD20 / γδTCR binding protein comprises a first heavy chain, a first light chain, a second heavy chain, and a second light chain, wherein:

[0180] (1) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:33 or having at least 80% or at least 90% identity with it.

[0181] The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80% or at least 90% identity with it.

[0182] The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:35 or having at least 80% or at least 90% identity with it.

[0183] The second light chain comprises an amino acid sequence as shown in SEQ ID NO:36 or having at least 80% or at least 90% identity with it;

[0184] or,

[0185] (2) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:33 or having at least 80% or at least 90% identity with it.

[0186] The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80% or at least 90% identity with it.

[0187] The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:37 or having at least 80% or at least 90% identity with it.

[0188] The second light chain comprises an amino acid sequence as shown in SEQ ID NO:38 or having at least 80% or at least 90% identity with it;

[0189] or,

[0190] (3) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:55 or having at least 80% or at least 90% identity with it.

[0191] The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80% or at least 90% identity with it.

[0192] The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:56 or having at least 80% or at least 90% identity with it.

[0193] The second light chain comprises an amino acid sequence as shown in SEQ ID NO:38 or having at least 80% or at least 90% identity with it.

[0194] host cells

[0195] This disclosure provides recombinant host cells that express or are capable of expressing one or more of the CD19 / CD20 / γδTCR binding proteins of this disclosure and / or contain polynucleotides or vectors of this disclosure. In some embodiments, the host cells are bacterial cells, fungal cells, or mammalian cells.

[0196] Bacterial cells include, for example, cells of Gram-negative bacterial strains (such as Escherichia coli, Proteus, and Pseudomonas strains) and Gram-positive bacterial strains (such as Bacillus, Streptomyces, Staphylococcus, and Lactococcus strains).

[0197] Fungal cells include, for example, cells of species from the genera *Trichoderma*, *Neurospora*, and *Aspergillus*; or cells of species from the genera *Saccharomyces* (e.g., *Saccharomyces cerevisiae*), *Schizosaccharomyces* (e.g., *Schizosaccharomyces pombe*), *Pichia* (e.g., *Pichia pastoris* and *Pichia methanolica*), and *Hansenula*.

[0198] Mammalian cells include, for example, HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, etc.

[0199] However, this disclosure may also use amphibian cells, insect cells, plant cells, and any other cells in the art used for expressing heterologous proteins.

[0200] Preparation method

[0201] This disclosure provides a method for preparing a CD19 / CD20 / γδTCR binding protein, comprising: expressing the target protein in a host cell as described above, and isolating the target protein from the host cell. Optionally, a purification step may be included, for example, purification using an A or G Sepharose FF column containing adjusted buffer to wash away non-specifically bound components, followed by elution of bound antibodies using a pH gradient, detection by SDS-PAGE, and collection. Optionally, filtration and concentration may be performed using conventional methods. Soluble mixtures and polymers may also be removed using conventional methods, such as molecular sieving or ion exchange. The obtained product should be immediately frozen, such as at -70°C, or lyophilized.

[0202] Methods for producing and purifying antibodies are well-known and available in existing technologies, such as Cold Spring Harbor’s Guide to Antibody Laboratory Techniques (Chapters 5-8 and 15).

[0203] The engineered antibodies or antigen-binding fragments disclosed herein can be prepared and purified using conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into expression vectors. Recombinant immunoglobulin expression vectors can stably transfect CHO cells. Mammalian expression systems lead to glycosylation of antibodies, particularly at the highly conserved N-terminus of the Fc region. Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones are scaled up in serum-free medium in a bioreactor to produce antibodies. Cultures secreting antibodies can be purified and collected using conventional techniques. Antibodies can be concentrated by filtration using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieving and ion exchange.

[0204] combination

[0205] This disclosure provides combinations comprising the aforementioned CD19 / CD20 / γδTCR binding protein, polynucleotide, or carrier. For example, a pharmaceutical composition is provided containing an effective amount of the aforementioned CD19 / CD20 / γδTCR binding protein for treating, alleviating, or preventing disease, and at least one pharmaceutically acceptable excipient, diluent, or excipient.

[0206] In some specific embodiments, the pharmaceutical composition may contain 0.01 to 99% by weight of CD19 / CD20 / γδTCR binding protein per unit dose, or the amount of CD19 / CD20 / γδTCR binding protein per unit dose may be 0.1-2000 mg. In some specific embodiments, it may be 1-1000 mg.

[0207] In some embodiments, an article or product (e.g., a pharmaceutical combination or kit) is provided, comprising the aforementioned CD19 / CD20 / γδTCR binding protein, polynucleotide, or carrier. Optionally, the article includes a container and a label. Containers include, for example, bottles, syringes, and test tubes. The container contains a pharmaceutical composition effective in treating a condition. A label on or attached to the container indicates that the pharmaceutical composition is used to treat the selected condition.

[0208] In some embodiments, the combination, article, or product includes T cells, such as γδT cells. In some embodiments, the CD19 / CD20 / γδTCR binding protein and the T cells are formulated for simultaneous, separate, or sequential administration.

[0209] In some implementation schemes, the aforementioned disease is a proliferative disorder or cancer.

[0210] In some embodiments, the disease is a B-cell tumor; in some embodiments, the disease is lymphoma; in some embodiments, the disease is B-cell lymphoma.

[0211] Treatment methods and pharmaceutical uses

[0212] This disclosure provides the aforementioned polynucleotides or carriers that encode polynucleotides, combinations thereof (including pharmaceutical compositions), for the treatment, relief, prevention, or diagnosis of diseases or conditions.

[0213] Some implementation schemes provide methods for improving, alleviating, treating, or preventing disease, including administering to a subject an effective amount for improving, alleviating, treating, or preventing the disease:

[0214] 1) The aforementioned CD19 / CD20 / γδTCR binding protein or its encoded polynucleotide, and pharmaceutical composition;

[0215] 2) The aforementioned CD19 / CD20 / γδTCR binding protein or its encoded polynucleotide, and pharmaceutical composition.

[0216] 3) Combinations, articles, or products containing the aforementioned CD19 / CD20 / γδTCR binding proteins.

[0217] In some implementations, the use of items 1)-3) above is provided for the preparation of a medicament to improve, alleviate, treat or prevent disease.

[0218] In some embodiments, a method is provided for treating diseases in combination with the CD19 / CD20 / γδTCR binding protein of this disclosure and γδT cells. In some embodiments, the γδT cells are autologous or allogeneic.

[0219] In some embodiments, any of the CD19 / CD20 / γδTCR binding proteins described above are used to treat diseases, including in combination with γδT cells. In some embodiments, γδT cells are used to treat diseases, including in combination with any of the CD19 / CD20 / γδTCR binding proteins described above.

[0220] In some embodiments, any of the CD19 / CD20 / γδTCR binding proteins described above are used to treat diseases, including in combination with γδT cells. In some embodiments, γδT cells are used to treat diseases, including in combination with any of the CD19 / CD20 / γδTCR binding proteins described above.

[0221] In some embodiments, a method of treating a disease is provided, comprising administering to a subject in need a therapeutically effective amount of any of the aforementioned CD19 / CD20 / γδTCR and γδT cells of this disclosure. In some embodiments, a method of treating a disease is provided, comprising administering to a subject in need a therapeutically effective amount of any of the aforementioned CD19 / CD20 / γδTCR binding protein and γδT cells of this disclosure.

[0222] In some implementations, the aforementioned disease is a disease or condition caused by the overexpression of CD19 and / or CD20.

[0223] In some implementation schemes, the aforementioned disease is a proliferative disorder or cancer.

[0224] In some specific implementations, the cancer is CD19 positive. In some specific implementations, the cancer is CD20 positive. In some specific implementations, the cancer is both CD19 and CD20 positive.

[0225] In some implementations, the aforementioned disease is a B-cell tumor; in some implementations, the disease is lymphoma; in some implementations, the disease is B-cell lymphoma.

[0226] Detection

[0227] This disclosure provides a CD19 / CD20 / γδTCR binding protein encoding a polynucleotide, and its use in the detection of compositions thereof. This disclosure also provides methods, systems, or apparatus for the in vivo or in vitro detection of CD19, CD20, and TRGV9, comprising treating a sample with the aforementioned binding protein, polynucleotide, or composition of this disclosure.

[0228] In some embodiments, a kit is also provided comprising the aforementioned CD19 / CD20 / γδTCR binding protein, encoding a polynucleotide, a composition, and may also include diagnostic instructions for use. The kit may also contain at least one additional reagent, such as a marker or additional diagnostic agent. For in vivo use, the CD19 / CD20 / γδTCR binding protein, encoding a polynucleotide, may be formulated as a pharmaceutical composition.

[0229] Terminology Definition

[0230] To facilitate understanding of this disclosure, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined in this disclosure, all other technical and scientific terms used in this disclosure shall have the meaning commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0231] The three-letter and single-letter codes for amino acids used in this disclosure are as described in J. Biol. Chem., 243, p3558 (1968).

[0232] "TRGV9" refers to a polypeptide that, when expressed on the surface of γδT cells, can form a T cell receptor. γδT cells expressing TRGV9 are among the earliest T cells to develop in human fetuses and are the major γδT cell subset in the peripheral blood of healthy adults. "TRGV9" includes any TRGV9 variant, isotype, and species homolog that is naturally expressed by cells (including T cells) or that can be expressed on cells transfected with a gene or cDNA encoding the polypeptide. In a specific embodiment, TRGV9 is human TRGV9. An exemplary human TRGV9 amino acid sequence is provided by GenBank accession number NG_001336.2.

[0233] The term "CD19 / CD20 / γδTCR binding protein" encompasses any protein capable of specifically binding to CD19, CD20, and / or γδTCR, or any molecule containing said protein, including but not limited to antibodies, peptides, fusion proteins of antibodies and peptides, or conjugates thereof. In some embodiments, the "CD19 / CD20 / γδTCR binding protein" specifically binds to CD19, CD20, and γδTCR. In some embodiments, the term "CD19 / CD20 / γδTCR binding protein" encompasses the anti-CD19 / CD20 / γδTCR bispecific antibody described in the embodiments of this disclosure. In some embodiments, the "CD19 / CD20 / γδTCR binding protein" is a CD19 / CD20 / TRGV9 binding protein.

[0234] The term "antibody" encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., trispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), as long as they exhibit the desired antigen-binding activity. Antibodies can refer to immunoglobulins, which are tetrapeptide chains composed of two identical heavy chains and two identical light chains linked by interchain disulfide bonds. The amino acid composition and sequence of the constant region of the immunoglobulin heavy chain differ, thus their antigenicity also differs. Based on this, immunoglobulins can be divided into five classes, or isotypes of immunoglobulins: IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being μ, δ, γ, α, and ε chains, respectively. Within the same class of Ig, based on differences in the amino acid composition of the hinge region and the number and position of disulfide bonds in the heavy chain, different subclasses can be distinguished; for example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are classified as κ chains or λ chains based on differences in their constant regions. Each of the five classes of Ig can have either a κ chain or a λ chain. The sequence of approximately 110 amino acids near the N-terminus of the antibody heavy and light chains varies considerably, forming the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable, forming the constant region (C region). The variable region includes three hypervariable regions (HVR) and four relatively conserved framework regions (FR). The three hypervariable regions determine the antibody's specificity and are also known as complementarity-determining regions (CDR). Each light chain variable region (VL) and heavy chain variable region (VH) consists of three CDR regions and four FR regions, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.

[0235] As used herein, the term "trispecific antibody" refers to an antibody that is "at least three-specific," meaning it contains at least a first binding domain, a second binding domain, and a third antigen-binding domain. For example, the first binding domain binds to one antigen or target (e.g., γδTCR), the second binding domain binds to another antigen or target (e.g., CD19), and the third binding domain binds to another antigen or target (e.g., CD20). Therefore, a trispecific antibody according to this disclosure contains specificity against at least three different antigens or targets. The term "trispecific antibody" of this invention also encompasses multispecific antibodies, such as tetraspecific antibodies, or antibodies having more than four (e.g., five...) specificities.

[0236] The antibodies disclosed herein can be polyclonal, monoclonal, xenogeneic, allogeneic, syngeneic, or modified forms thereof, with monoclonal antibodies being particularly suitable in many embodiments. Generally, the antibodies disclosed herein are recombinant antibodies. As used herein, “recombinant” refers to products such as cells or nucleic acids, proteins, or vectors, indicating that said cells, nucleic acids, proteins, or vectors have been modified by introducing heterologous nucleic acids or proteins or by altering native nucleic acids or proteins, or that said cells are derived from such modified cells. For example, recombinant cells express genes not present in native (non-recombinant) cell forms or express native genes that are abnormally expressed, poorly expressed, or not expressed at all.

[0237] "Antigen-binding fragments" encompass single-chain antibodies (i.e., full-length heavy and light chains); Fab, modified Fab, Fab', modified Fab', F(ab')2, Fv, Fab-Fv, Fab-dsFv, single-domain antibodies (e.g., VH, VL, or VHH), scFv, bivalent, trivalent, or tetravalent antibodies, Bis-scFv, diabody, tribody, triabody, tetrabody, and epitope-binding fragments of any of the above (see, for example, Holliger and Hudson, 2005, Nature Biotech. 23(9): 1126-1136; Adair and Lawson, 2005, Drug Design Reviews-Online 2(3), 209-217). Methods for generating and preparing these antigen-binding fragments are well known in the art (see, for example, Verma et al., 1998, Journal of Immunological Methods, 216, 165-181).

[0238] The determination or definition of a CDR can be accomplished by resolving the structure of the antibody and / or the structure of the antibody-ligand complex, thereby enabling the definitive depiction of the CDR and the identification of residues containing the antibody binding site. This can be achieved using any of the various techniques known to those skilled in the art, such as X-ray crystallography. A variety of analytical methods can be used to identify CDRs, including but not limited to the Kabat numbering system, the Chothia numbering system, the AbM numbering system, the IMGT numbering system, contact definition, and conformation definition. The Kabat numbering system is the standard for numbering residues in antibodies and is commonly used to identify CDR regions (see, for example, Johnson & Wu, 2000, Nucleic Acids Res., 28: 214-8). The Chothia numbering system is similar to the Kabat numbering system, but it takes into account the location of certain structural loop regions (see, for example, Chothia et al., 1986, J. Mol. Biol., 196: 901-17; Chothia et al., 1989, Nature, 342: 877-83). The AbM numbering system uses a computer program integration suite produced by the Oxford Molecular Group to model antibody structures (see, for example, Martin et al., 1989, ProcNatl Acad Sci (USA), 86: 9268-9272; "AbMTM, A Computer Program for Modeling Variable Regions of Antibodies," Oxford, UK; Oxford Molecular, Ltd). The AbM numbering system uses a combination of knowledge databases and a de novo approach to model the tertiary structure of antibodies from basic sequences (see those described in Samudrala et al., 1999, "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach" in PROTEINS, Structural, Function and Genetics Suppl., 3: 194-198). Contact definitions are based on the analysis of available complex crystal structures (see, for example, MacCallum et al., 1996, J. Mol. Biol., 5: 732-45). In the conformational definition, the position of CDR can be identified as a residue that contributes enthalpy to antigen binding (see, for example, Makabe et al., 2008, Journal of Biological Chemistry, 283: 1156-1166).Other CDR boundary definitions may not strictly follow one of the methods described above, but still overlap with at least a portion of the Kabat CDR, although they may be shortened or lengthened depending on the predicted or experimental results that a particular residue or group of residues does not significantly affect antigen binding. As used in this disclosure, a CDR may refer to a CDR defined by any method (including combinations of methods) known in the art. The correspondence between various numbering systems is well known to those skilled in the art.

[0239] A "domain" of a polypeptide or protein refers to a folded protein structure that can maintain its tertiary structure independently of the rest of the protein. Generally, a domain is responsible for a single functional property of a protein and, in many cases, can be added to, removed from, or transferred to other proteins without losing the function of the rest of the protein and / or the domain itself.

[0240] An "immunoglobulin domain" refers to a globular region of an antibody chain (such as the chain of a conventional tetrapeptide chain antibody or a heavy chain antibody), or a polypeptide that is essentially composed of such globular regions. An immunoglobulin domain is characterized by its ability to maintain the immunoglobulin folding properties of the antibody molecule, consisting of two interlayers of approximately seven antiparallel β-sheet strands arranged in two β-sheets, optionally stabilized by conserved disulfide bonds.

[0241] An immunoglobulin variable domain refers to an immunoglobulin domain essentially composed of four "frame regions," referred to in the art and hereinafter as "frame region 1" or "FR1," "frame region 2" or "FR2," "frame region 3" or "FR3," and "frame region 4" or "FR4," respectively. These frame regions are separated by three "complementarity-determining regions" or "CDRs," referred to in the art and hereinafter as "complementarity-determining region 1" or "CDR1," "complementarity-determining region 2" or "CDR2," and "complementarity-determining region 3" or "CDR3," respectively. Therefore, the general structure or sequence of an immunoglobulin variable domain can be represented as: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The immunoglobulin variable domain confers antigen specificity due to the presence of antigen-binding sites.

[0242] "Antibody framework (FR)" refers to a portion of a variable domain that serves as a scaffold for the antigen-binding loop (CDR) of that variable domain.

[0243] "Immunoglobulin single variable domain" is generally used to refer to an immunoglobulin variable domain (which can be a heavy chain or light chain domain, including VH, VHH, or VL domains) that can form a functional antigen-binding site without interacting with other variable domains (e.g., without the VH / VL interaction required between the VH and VL domains of a conventional four-chain monoclonal antibody). Examples of "immunoglobulin single variable domain" include nanobodies (including VHH, humanized VHH, and / or camelified VH, such as camelified human VH), IgNAR, domains, and (single-domain) antibodies (such as dAbs) that are VH domains or derived from VH domains. TM ) and antibodies that are VL domains or derived from VL domains (such as dAbs) TM Immunoglobulin single variable domains based on and / or derived from heavy chain variable domains (such as VH or VHH domains) are generally preferred. A specific example of an immunoglobulin single variable domain is the “VHH domain” (or simply “VHH”) as defined below.

[0244] "VHH" is also known as heavy chain single-domain antibody, VHH, V H The H domain, VHH antibody fragment, VHH antibody, and nanobody are variable domains of antigen-binding immunoglobulins called "heavy chain antibodies" (i.e., "antibodies lacking light chains") (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: "Naturally occurring antibodies devoid of light chains"; Nature 363, 446-448 (1993)). The term "VHH" is used to distinguish the variable domain from the heavy chain variable domain (referred to herein as the "VH domain" or VH) and light chain variable domain (referred herein as the "VL domain" or VL) present in conventional tetrapeptide chain structure antibodies. The VHH domain specifically binds to epitopes without the need for other antigen-binding domains (unlike the VH or VL domains in conventional tetrapeptide chain structure antibodies, in which case the epitope is recognized by the VL domain along with the VH domain). The VHH domain is a small, stable, and highly efficient antigen recognition unit formed by a single immunoglobulin domain. Terms include "heavy chain single-domain antibody," "VHH domain," "VHH," and "V..." H "H domain", "VHH antibody fragment", "VHH antibody", as well as" The term "domain" ("Nanobody" is a trademark of Ablynx NV, Ghent, Belgium) is used interchangeably. VHHs include, but are not limited to, naturally occurring antibodies produced by camelids, or antibodies produced by camelids that have been humanized, or those obtained through phage display technology. The total number of amino acid residues in a VHH will typically be in the range of 110 to 120, often between 112 and 115. However, it should be noted that smaller and longer sequences may also be suitable for the purposes described in this disclosure. Methods for obtaining VHHs that bind to specific antigens or epitopes have previously been disclosed in the following literature: R. van der Linden et al., Journal of Immunological Methods, 240(2000)185-195; Li et al., J Biol Chem., 287(2012)13713-13721; Deffar et al., African Journal of Biotechnology Vol.8(12), pp.2645-2652, 17 June, 2009 and WO94 / 04678.

[0245] As is known in the art regarding VH and VHH domains, the total number of amino acid residues in each CDR may differ and may not correspond to the total number of amino acid residues indicated by the Kabat number (i.e., one or more positions according to the Kabat number may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than allowed by the Kabat number). This means that, in general, the Kabat number may or may not correspond to the actual number of amino acid residues in the actual sequence. Other numbering systems or encoding rules include Chothia, IMGT, and AbM.

[0246] "Humanized antibody," also known as CDR-grafted antibody, refers to an antibody generated by grafting a non-human CDR sequence into the variable region framework of a human antibody. This can overcome the strong immune response induced by chimeric antibodies due to the presence of a large number of non-human protein components. To avoid a decrease in activity along with a decrease in immunogenicity, the variable region of the fully human antibody can be minimally reverse-mutated to maintain activity. Examples of "humanization" include the substitution of a VHH domain derived from camelids with one or more amino acid residues in the original VHH sequence by replacing one or more amino acid residues present at the corresponding position in the VH domain of a conventional human tetrapeptide chain antibody (also referred to herein as "sequence optimization"; in addition to humanization, "sequence optimization" may also encompass other modifications to the sequence by providing one or more mutations that enhance the properties of the VHH, such as removing potential post-translational modification sites). The humanized VHH domain may contain one or more fully human framework region sequences, and in some specific embodiments, may contain the human framework region sequence of IGHV3. Humanization methods include protein surface amino acid resurfacing and antibody humanization using a universal framework grafting method (CDR grafting to a universal framework), which involves "grafting" the CDR onto other "scaffolds" (including but not limited to human scaffolds or non-immunoglobulin scaffolds). Suitable scaffolds and techniques for CDR grafting are known in the art. Germline DNA sequences of human heavy and light chain variable region genes, for example, can be found in the VBase human germline sequence database and in Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest, 5th edition. The humanized antibodies disclosed herein also include humanized antibodies further matured by phage display with affinity for the CDR. Furthermore, to avoid a decrease in activity along with a decrease in immunogenicity, minimal reverse or reversion mutations can be performed on the human antibody variable region framework sequence to maintain activity.

[0247] "Binding affinity" or "affinity" is used in this disclosure as a measure of the strength of a non-covalent interaction between two molecules (e.g., an antibody or a portion thereof with an antigen). The binding affinity between two molecules can be determined by determining the dissociation constant (K). D Quantification can be achieved by using methods such as surface plasmon resonance (SPR) (Biacore) to measure the kinetics of complex formation and dissociation. D The rate constants corresponding to the binding and dissociation of monovalent complexes are called the binding rate constant ka (or kon) and the dissociation rate constant kd (or koff), respectively.D Through equation K D =kd / ka is related to ka and kd. The value of the dissociation constant can be determined directly by well-known methods, and even for complex mixtures, it can be calculated using methods such as those described by Caceci et al. (1984, Byte 9: 340-362). For example, K can be determined using a double-filtered nitrocellulose filter combined with determinations such as those disclosed in Wong & Lohman (1993, Proc. Natl. Acad. Sci. USA 90: 5428-5432). D Other standard assays for assessing the binding ability of antibodies to target antigens are known in the art, including, for example, ELISA, Western blotting, RIA, and flow cytometry, as well as other assays exemplified elsewhere in this disclosure. Antibody binding kinetics and binding affinity can also be determined using standard assays known in the art, such as surface plasmon resonance (SPR), for example, by using Biacore. TM Evaluation can be performed using a system or KinExA. The Kelvin values ​​of individual antibody / antigen complexes can be compared. D The binding affinity is used to compare the binding affinity of different molecules associated with their interactions, for example, comparing the binding affinity of different antibodies for a given antigen. Similarly, the specificity of an interaction can be determined and compared by identifying and comparing the K-value of the target interaction (e.g., the specific interaction between an antibody and an antigen). D Values ​​of K for non-target interactions (e.g., control antibodies known not to bind to CD19, CD20, γδTCR, or CD16A) D The value is evaluated.

[0248] "Conservative substitution" refers to the substitution with another amino acid residue that has properties similar to the original amino acid residue. For example, lysine, arginine, and histidine have similar properties in that they have basic side chains, and aspartic acid and glutamic acid have similar properties in that they have acidic side chains. Furthermore, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, and tryptophan have similar properties in that they have uncharged polar side chains, and alanine, valine, leucine, threonine, isoleucine, proline, phenylalanine, and methionine have similar properties in that they have nonpolar side chains. Additionally, tyrosine, phenylalanine, tryptophan, and histidine have similar properties in that they have aromatic side chains. Therefore, it will be apparent to those skilled in the art that even when amino acid residues in the group exhibiting similar properties as described above are substituted, it will not show a specific change in properties.

[0249] "Homology," "identity," or "sequence identity" refers to the sequence similarity between two polynucleotide sequences or two polypeptides. When positions in two compared sequences are occupied by the same nucleotide or amino acid monomer—for example, if every position in two DNA molecules is occupied by the same nucleotide—then the molecules are homologous at that position. The percentage of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared multiplied by 100%. For example, at optimal sequence alignment, if six out of ten positions in two sequences match or are homologous, then the two sequences are 60% homologous. Generally, comparisons are made when the highest percentage of homology is obtained by aligning the two sequences.

[0250] The terms "nucleic acid" and "polynucleotide" are used interchangeably in this disclosure and refer to any single-stranded or double-stranded DNA or RNA molecule, and in the case of a single-stranded molecule, its complementary sequence, preferably double-stranded DNA. When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, the nucleic acid is "effectively linked." For example, if a promoter or enhancer affects the transcription of a coding sequence, then the promoter or enhancer is effectively linked to said coding sequence.

[0251] "Host cell" includes individual cells or cell cultures that may be, or have been, recipients of vectors for incorporating polynucleotide inserts. Host cells include progeny of a single host cell, and progeny may not necessarily be identical to the original parent cell (in morphology or genomic DNA complementation) due to natural, accidental, or intentional mutations. Host cells include cells transfected and / or transformed in vivo with the polynucleotides of this disclosure. "Cell," "cell line," and "cell culture" are used interchangeably, and all such names include their progeny. It should also be understood that, due to intentional or unintentional mutations, all progeny may not be exactly identical in DNA content. This includes mutant progeny with the same function or biological activity as those screened from the originally transformed cells.

[0252] "Inhibit" or "block" are used interchangeably and cover both partial and complete inhibition / blockage. "Inhibit growth" (e.g., involving cells) is intended to include any measurable reduction in cell growth.

[0253] "Giving," "applying," and "treatment," when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refer to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with the animal, human, subject, cell, tissue, organ, or biological fluid, such as in therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Cellular treatment includes contact between a reagent and a cell, as well as contact between a reagent and a fluid, wherein the fluid is in contact with the cell. "Giving," "applying," and "treatment" also mean treatment, such as of cells, by means of a reagent, diagnostic agent, conjugate composition, or by means of another cell in vitro and ex vivo. When applied to humans, veterinary, or research subjects, it refers to therapeutic treatment, preventative or prophylactic measures, research, and diagnostic applications.

[0254] "Treatment" means administering, either internally or externally, a therapeutic agent, such as a pharmaceutical composition comprising any of the binding proteins of this disclosure or thereof, to a subject who has, is suspected of having, or is predisposed to having one or more proliferative diseases or their symptoms, and the therapeutic agent is known to have a therapeutic effect on these symptoms. Typically, the therapeutic agent is administered in a treated subject or population in an amount that effectively relieves symptoms of one or more diseases, whether by inducing the regression of such symptoms or inhibiting their development to any clinically measurable degree. The amount of therapeutic agent that effectively relieves symptoms of any specific disease (also referred to as the "therapeuticly effective amount") can vary depending on a variety of factors, such as the subject's disease state, age, and weight, and the drug's ability to produce the desired therapeutic effect in the subject. Whether the disease symptoms have been relieved can be evaluated using any clinical test method commonly used by a physician or other healthcare professional to assess the severity or progression of the symptoms. Although the embodiments of this disclosure (e.g., treatment methods or products) may be ineffective in alleviating the symptoms of the target disease in a particular subject, they should reduce the symptoms of the target disease in a statistically significant number of subjects, as determined by any statistical test known in the art, such as the Student t-test, chi-square test, U-test according to Mann and Whitney, Kruskal-Wallis test (H-test), Jonckheere-Terpstra test, and Wilcoxon test.

[0255] "Effective amount" includes an amount sufficient to improve or prevent the symptoms or condition of a medical condition. Effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount used on a subject may vary depending on factors such as the condition to be treated, the subject's overall health, the route and dosage of administration, and the severity of side effects. Effective amount may be the maximum dose or administration regimen that avoids significant side effects or toxicity. Subjects in this disclosure may be animal or human subjects.

[0256] "Optional" or "optionally" means that the event or circumstance described subsequently may, but does not necessarily, occur, and the description includes the possibility that the event or circumstance may or may not occur. "And / or" should be considered as specifically disclosing that each of the two specified features or components has or does not have the other. Therefore, the term "and / or" as used in phrases such as "A and / or B" in this disclosure includes "A and B," "A or B," "A" (alone), and "B" (alone). Unless the context clearly requires otherwise, throughout the specification and claims, the words "comprising," "having," "including," etc., should be understood to have an inclusive meaning rather than an exclusive or exhaustive meaning; that is, the meaning of "including but not limited to." In the context of mutations contained in the Fc region in this disclosure, " / " means "and," for example, "L234A / L235A" means "L234A and L235A," that is, the Fc region contains the L234A and L235A mutations; the amino acid positions of the mutations in the Fc region of this disclosure are defined according to the EU numbering system.

[0257] In this disclosure, "subject" and "patient" include both human and non-human mammals. Similarly, the term "subject" includes both human and veterinary subjects, such as non-human primates. Therefore, administration to a subject can include administration to a human subject. Non-limiting examples of veterinary subjects include domestic animals (e.g., cats and dogs), livestock (e.g., cattle, horses, pigs, sheep, and goats), and laboratory animals (e.g., mice, rabbits, rats, gerbils, guinea pigs, and non-human primates). Attached Figure Description

[0258] Figure 1 is a schematic diagram of the molecular structure of the anti-CD19 / CD20 / γδT triple antibody.

[0259] Figures 2A and 2B show the binding activity of anti-CD19 / CD20 / γδT antibodies against human CD19 and CD20 positive cells. Figure 2A shows the binding activity with K562-human CD19, and Figure 2B shows the binding activity with K562-human CD20.

[0260] Figures 3A and 3B show the binding activity of the CD19 / CD20 / γδT antibody against monkey-derived CD19 and CD20-positive cells. Figure 3A shows the binding activity with K562-monkey CD19, and Figure 3B shows the binding activity with K562-monkey CD20.

[0261] Figures 4A and 4B show the cytotoxic activity of anti-CD19 / CD20 / γδT antibodies against cells with different CD19 / CD20 expression levels. Figure 4A shows the cytotoxic activity against Daudi cells, Figure 4B shows the cytotoxic activity against Raji cells, Figure 4C shows the cytotoxic activity against WSU-DLCL2 cells, and Figure 4D shows the cytotoxic activity against RS4;11 cells.

[0262] Figures 5A to 5C show the antitumor activity of the anti-CD19 / CD20 / γδT antibody against Daudi tail vein tumors in NOG mice. Figure 5A shows the fluorescence values ​​for each group, Figure 5B shows the changes in mouse body weight, and Figure 5C shows the fluorescence images.

[0263] Figures 6A and 6B show the antitumor activity of anti-CD19 / CD20 / γδT antibody against WSU-DLCL2 subcutaneous tumors in NOG mice. Figure 6A shows the tumor volume in each group, and Figure 6B shows the changes in mouse body weight. ** represents vs. G2, P<0.01

[0264] Figure 7 shows the in vitro binding activity of the anti-CD19 / CD20 / γδT antibody in Raji cells, which are CD19 and CD20 double-positive.

[0265] Figure 8 shows the in vitro killing activity of the anti-CD19 / CD20 / γδT antibody against CD19CD20 double-positive Raji cells.

[0266] Figures 9A to 9C show the in vitro killing activity of anti-CD19 / CD20 / γδT antibody against B cells in PBMC cells. Detailed Implementation

[0267] Example

[0268] The following embodiments are used to further describe this disclosure, but these embodiments are not intended to limit the scope of this disclosure.

[0269] Experimental methods not specifically described in the embodiments or test examples of this disclosure are generally performed under conventional conditions or as recommended by the raw material or product manufacturer. See Sambrook et al., Molecular Cloning, Laboratory Manual, Cold Spring Harbor Laboratory; Methods in Modern Molecular Biology, Ausubel et al., Greene Publishing Association, Wiley Interscience, NY. Reagents not specifically named are commercially available, conventional reagents.

[0270] Example 1. Design and preparation of γδT antigen

[0271] The TCR (γδT cell receptor) on the surface of γδT cells is a heterodimeric membrane protein composed of γ and δ chains. Amino acids 1-242 of the γ9 chain (Protein data bank, 1HXM, chain B) of the human γδTCR extracellular region were selected, with a 3C restriction enzyme site, a leucine zipper, and a FLAG tag added sequentially to the C-terminus. Amino acids 1-229 of the δ2 ​​chain (Protein data bank, 1HXM, chain A) of the human γδTCR extracellular region were selected, with a 3C restriction enzyme site, a leucine zipper, and a His8 tag added sequentially to the C-terminus. Furthermore, Q180C and V168C mutations were introduced into the constant regions of the γ and δ chains, respectively, to form interchain disulfide bonds, further reducing homodimerization mismatch between the γ and δ chains. The recombinant monkey (Macaca mulatta) γ9δ2TCR protein was obtained by selecting amino acids 1-241 of the monkey γ9 chain (sequence published in patent number: US2019144540A1SEQ ID NO:42), with a 3C restriction site, a leucine zipper, and a FLAG tag added sequentially to the C-terminus; amino acids 1-229 of the monkey δ2 chain (sequence published in patent number: US20190144540A1SEQ ID NO:37) were selected, with a 3C restriction site, a leucine zipper, and a His8 tag added sequentially to the C-terminus; in addition, Q179C and V168C mutations were introduced into the constant regions of the γ and δ chains, respectively, to form interchain disulfide bonds.

[0272] Recombinant human γ9 chain (Q180C)

[0273] Recombinant human δ2 chain (V168C)

[0274] Recombinant monkey γ9 chain (Q179C)

[0275] Recombinant monkey δ2 chain (V168C)

[0276] Plasmids (pTT5 vectors) carrying the target protein encoding genes were synthesized separately. Plasmids encoding recombinant human γ9 chain (SEQ ID NO:57) and human δ2 chain (SEQ ID NO:58) were mixed in a 1:1 ratio. Plasmids encoding recombinant monkey γ9 chain (SEQ ID NO:59) and monkey δ2 chain (SEQ ID NO:60) were mixed in a 1:1 ratio and transfected into Expi293 cells (purchased from Thermo). After transient transfection and expression for 7 days, the supernatant was collected after centrifugation at 4°C and purified by His-tag purification resin to obtain recombinant human γ9δ2 TCR protein and monkey γ9δ2 TCR protein. The proteins were stored at -80°C for later use.

[0277] Example 2. Screening of anti-γδT single-domain antibodies

[0278] Adult healthy alpacas were immunized with in vitro expanded human γ9δ2 T cells as immunogens, and specific antibodies were screened using the recombinant human γ9δ2 TCR protein from Example 1 via phage display.

[0279] Specifically, the initial immunization dose was 2E7 cells per alpaca. Three weeks after the initial immunization, a booster immunization was administered at a dose of 2E7 cells per alpaca. Subsequent booster immunizations were administered at 3-week intervals. Serum samples were collected one week after each booster immunization, and antibody titers in the alpaca serum were detected using Protein ELISA and FACS.

[0280] The specific procedure for protein ELISA detection is as follows: Recombinant human γ9δ2TCR protein was diluted to 2 μg / mL with 0.05 M carbonate buffer (pH 9.6), 100 μL / well, and coated overnight at 4°C; the plate was blocked with PBST buffer containing 5% skim milk for 1 hour, and washed 3 times; alpaca serum was serially diluted 1:2000 in blocking buffer, incubated at 37°C for 45 min, and washed 5 times; 100 μL of horseradish peroxidase-conjugated goat anti-Alpaca IgG secondary antibody (AlpVHHs, 053-404-005, diluted 1:10000 with PBS) was added to each well, and the plate was incubated at 37°C for 45 min, and washed 5 times. Finally, 100 μL of TMB chromogenic solution was added to each well for color development, and 50 μL of stop solution was added after 5 minutes to terminate the reaction. The absorbance at 450 nm was read using a microplate reader.

[0281] The specific FACS detection procedure is as follows: Collect cells and resuspend them to 4E6 / mL. Add serially diluted alpaca serum to 50 μL of cells and incubate at 4°C for 1 hour. Wash twice with 1% BSA / PBS buffer, discard the supernatant, add 1:200 diluted Anti alpaca IgG iFluor647 (AlpVHHs, 053-404-009), and incubate at 4°C in the dark for 45 min. Wash twice with 1% BSA / PBS buffer, resuspend in 200 μL buffer, and then perform FACS detection.

[0282] Tests showed that the serum titer of the immunized alpaca was greater than 128 kJ.

[0283] One week after each of the three immunizations, 50 mL of peripheral blood was collected to separate lymphocytes (PBMCs). Total RNA was extracted from the PBMCs using RNAisoPlus reagent to construct a phage library, which yielded a phage library with a capacity of 2.56E9.

[0284] Antibodies against recombinant human γ9δ2 TCR protein were panned using phage display. Antibodies cross-binding with monkey γ9δ2 TCR protein were identified using ELISA, and antibodies against in vitro amplified human γ9δ2 TCR protein were determined using FACS.

[0285] Binding activity to γ9δ2T cells. Positive monoclonal single-domain antibodies were screened using the above ELISA and FACS detection methods, and their sequences are as follows.

[0286] >SDP01346 Variable Area

[0287] Table 1. CDR sequences of anti-human γδTCR single-domain antibodies (Kabat numbering rules)

[0288] Example 3. Construction and functional validation of anti-γδTCR chimeric antibody

[0289] 1. Expression of chimeric antibodies

[0290] The nucleotide sequence encoding the single-domain antibody was cloned into the pTT5 vector and transfected into ExpiCHO cells. After 8 days, the cells were centrifuged to remove the cells, and the cell culture medium was collected and filtered. The harvested cell culture medium was purified using a nickel affinity column (HisTrap excel, GE). The bound antibody was eluted with 300mM imidazole, and the medium was desalted and replaced with PBS to obtain the target antibody.

[0291] SDP01346 full length

[0292] 2. Binding of chimeric antibodies to γ9δ2 T cells

[0293] The procedure for detecting the cellular affinity of anti-γδTCR single-domain antibodies is as follows: The serially diluted antibody molecules are placed in a 1×10⁻⁶ medium... 5 γ9δ2T cells were incubated at 4°C for 1 hour. After washing away excess antibody, DyLight 405-AffiniPure Goat Anti-Alpaca IgG and VHH domain antibody (Jackson, Cat#128-475-232) were added and incubated at 4°C for 30 minutes. After washing away excess antibody, the cells were resuspended in 200 μL of 2% FBS / PBS buffer and the fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer. The results are shown in Table 2.

[0294] Table 2. Binding ability of anti-γδTCR chimeric antibodies

[0295] The results showed that SDP01346 had good binding activity on γ9δ2T cells.

[0296] Example 4. Identification of the antigen-binding region of anti-γδTCR antibody

[0297] This embodiment uses a protein-based ELISA to detect the binding region between the anti-γδTCR antibody and the antigen. Using a method similar to that in Example 1, recombinant human γ9δ1TCR protein (dimeric proteins of SEQ ID NO:57 and SEQ ID NO:63), human γ8δ2TCR protein (dimeric proteins of SEQ ID NO:64 and SEQ ID NO:58), human VγδCαβ chimeric TCR protein (dimeric proteins of SEQ ID NO:65 and SEQ ID NO:66), and human VαβCγδ chimeric TCR protein (dimeric proteins of SEQ ID NO:67 and SEQ ID NO:68) were prepared.

[0298] The binding activity of anti-γδTCR antibodies to the aforementioned antigens was identified using ELISA to determine the approximate binding region. The specific detection procedure for the Protein ELISA is as follows: 1 μg / mL of recombinant TCR protein was coated onto plates and incubated overnight at 4°C. The plates were then blocked with PBST buffer containing 1% BSA for 1 hour and washed three times. The antibody was diluted to 30 nM with blocking buffer and incubated at 37°C for 1 hour. After washing three times, the plates were incubated with a 1:10000 dilution of anti-Goat Anti-Alpaca IgG, VHH domain antibody for 1 hour. The plates were washed three times with PBST, and 100 μL TMB chromogenic buffer was added to each well for color development. The reaction was terminated with stop solution after 15 minutes. The absorbance at 450 nm was read using a microplate reader.

[0299] Recombinant human δ1 chain

[0300] Recombinant human γ8 chain

[0301] Recombinant human Vγ9Cβ chain

[0302] Recombinant human Vδ2Cα chain

[0303] Recombinant human Vβ7Cγ chain

[0304] Recombinant human Vα13Cδ chain

[0305] The ELISA results are shown in Table 3. The absorbance values ​​of antibody SDP01346 for different antigens are different. If the absorbance value is more than twice the background value (about 0.1), it is determined to be bound to the same antigen. As shown in Table 3, this antibody binds to the γ9δ1TCR protein but not the γ8δ2TCR protein, indicating that the antibody binds to the γ9 chain; this antibody binds to the VγδCαβ chimeric TCR protein but not the VαβCγδ chimeric TCR, indicating that the antibody binds to the variable region (V region) of the TCR. In summary, it can be clearly concluded that antibody SDP01346 binds to TRGV9.

[0306] Table 3. Identification results of chimeric antibody-antigen binding regions

[0307] Example 5. Humanization of anti-γδTCR antibody

[0308] The variable region sequence was compared with the antibody germline database to obtain a human germline template with high homology. Among them, the human germline heavy chain template used for SDP01346 was IGHV3-30. After predicting the structure of the monoclonal antibody through homology modeling, the CDR of the single-domain antibody was embedded into a suitable human GermLine frame (Bioinformation.2014;10(4):180-186;Methods Mol Biol.2019;1904:213-230), and then a reversion mutation was introduced into the frame region.

[0309] The obtained humanized molecule sequence is as follows:

[0310] >SDP01346 VH1

[0311] >SDP01346 VH2

[0312] >SDP01346 VH3

[0313] >SDP01346 VH4

[0314] After humanization of the single-domain antibody, a full-length antibody was constructed, and GGGGSHHHHHHH (SEQ ID NO:72) was added after the corresponding VHH.

[0315] Table 4. Correspondence between antibody names and antibody structures.

[0316] The following example provides the full-length sequence of SDP01378.

[0317] SDP01378 full length

[0318] The following section describes the FACS assay for the binding of humanized monoclonal antibody to γ9δ2T cells.

[0319] Affinity assay for humanized single-domain antibody SDP01346: The serially diluted antibody molecules were analyzed at 1×10⁻⁶... 5 γ9δ2T cells were incubated at 4°C for 1 hour. Excess antibody was washed away, and DyLight 405-AffiniPure Goat Anti-Alpaca IgG, VHH domain antibody (Jackson, Cat#128-475-232) was added. The cells were incubated at 4°C for 30 minutes, and after washing away excess antibody, they were resuspended in 200 μL of 2% FBS / PBS buffer. The fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer. The results are shown in Table 5. The humanized molecule SDP01346 exhibited good binding activity on γ9δ2T cells.

[0320] Table 5. Affinity Detection of Humanized Molecules in SDP01346

[0321] Example 6. Design and preparation of anti-CD19 / CD20 / γδTCR trispecific antibody

[0322] In this embodiment, three specific antibodies against CD19 / CD20 / γδTCR, namely SDP04908, SDP04909 and SDP11431, were designed.

[0323] The molecules SDP04908, SDP04909, and SDP11431 (as shown in Figure 1) contain two heavy chains and two light chains. The CDRs used at the CD19 ends of SDP04908, SDP04909, and SDP11431 are shown in SEQ ID NO:1-6, and the variable regions (VH) of the heavy chain and the variable regions (VL) of the light chain are shown in SEQ ID NO:22-23; the CDRs used for the γδTCR binding domain are shown in SEQ ID NO:13-15, and the single variable domain (VHH) is shown in SEQ ID NO:28. The CDR used at the CD20 end of SDP04908 is shown in SEQ ID NO:7-12, and the variable regions (VH) of the heavy chain and the variable regions (VL) of the light chain are shown in SEQ ID NO:24-25; the CDR used at the CD20 ends of SDP04909 and SDP11431 is shown in SEQ ID NO:16-21, and the variable regions (VH) of the heavy chain and the variable regions (VL) of the light chain are shown in SEQ ID NO:26-27.

[0324] To prevent and reduce heavy chain and light chain mismatches, Obscurin-O and Titin-T are used (SEQ ID NO:29-30), and CH1 and Cκ are used (SEQ ID NO:31-32). To prevent and reduce heavy chain mismatches, SDP04908 and SDP04909 use Fc1 and Fc2 with KIH mutations and employ LFLE mutations to weaken the Fc region effector function; their Fc1 and Fc2 sequences are shown in SEQ ID NO:39-40. SDP11431 uses Fc1 and Fc2 with KIH mutations and employs LALADS mutations to weaken the Fc region effector function; its Fc1 and Fc2 sequences are shown in SEQ ID NO:74-75.

[0325] The heavy chain sequence of SDP04908 is shown in SEQ ID NO:33 and 35, and the light chain sequence is shown in SEQ ID NO:34 and 36. The heavy chain sequence of SDP04909 is shown in SEQ ID NO:33 and 37, and the light chain sequence is shown in SEQ ID NO:34 and 38. The heavy chain sequence of SDP11431 is shown in SEQ ID NO:55 and 56, and the light chain sequence is shown in SEQ ID NO:34 and 38.

[0326] Table 6. CDR (Kabat numbering rule) for anti-CD19 / CD20 / γδTCR trispecific antibodies

[0327] Table 7. Structures of anti-CD19 / CD20 / γδTCR trispecific antibodies

[0328] >SDP04908, SDP04909, SDP11431 (CD19 end) VH1

[0329] >SDP04908, SDP04909, SDP11431 (CD19 end) VL1

[0330] >SDP04908 (CD20 end) VH2

[0331] SDP04908 (CD20 end) VL2

[0332] >SDP04909, SDP11431 (CD20 end) VH2

[0333] >SDP04909, SDP11431 (CD20 end) VL2

[0334] >SDP04908, SDP04909, SDP11431 (γδTCR end) VHH

[0335] Obscurin-O

[0336] Titin-T

[0337] CH1

[0338] >Cκ

[0339] >SDP04908, SDP04909(CD19)H1

[0340]

[0341] >SDP04908, SDP04909, SDP11431(CD19)L1

[0342] >SDP04908(γδTCR-CD20)H2

[0343] >SDP04908(CD20)L2

[0344] >SDP04909(γδTCR-CD20)H2

[0345] >SDP04909, SDP11431(CD20)L2

[0346] >SDP11431 H1

[0347] >SDP11431 H2

[0348] >IgG1 Fc1(Y349C / T366S / L368A / Y407V / L234F / L235E)

[0349] >IgG1Fc2(S354C / T366W / L234F / L235E)

[0350] >IgG1Fc1(Y349C / T366S / L368A / Y407V / L234A / L235A / D265S)

[0351] >IgG1Fc2(S354C / T366W / L234A / L235A / D265S)

[0352] In the above sequence, the underlined line represents CDR, the underlined curve represents connector, and the italic text represents the Fc region.

[0353] The polynucleotide sequences encoding the trispecific antibodies were cloned into a pTT5-containing vector and transfected into CHOK1 cells. After expression and purification using standard methods, the target antibodies SDP04908, SDP04909, and SDP11431 were obtained.

[0354] The control antibody sequence used in this disclosure is as follows:

[0355] Anti-CD19 / γδTCR antibody SDP07309H1

[0356] Anti-CD19 / γδTCR antibody SDP07309L1

[0357] Anti-CD19 / γδTCR antibody SDP07309H2

[0358] Anti-CD19 / γδTCR antibody SDP07309L2

[0359] Anti-CD20 / γδTCR antibody SDP07310H1

[0360] Anti-CD20 / γδTCR antibody SDP07310L1

[0361] Anti-CD20 / γδTCR antibody SDP07310H2

[0362] Anti-CD20 / γδTCR antibody SDP07310L2

[0363] Anti-CD20 / γδTCR antibody SDP07311H1

[0364] Anti-CD20 / γδTCR antibody SDP07311L1

[0365] Anti-CD20 / γδTCR antibody SDP07311H2

[0366] Anti-CD20 / γδTCR antibody SDP07311L2

[0367] >Connector

[0368] >Connector

[0369] Example 7. Detection of antigen-binding affinity of anti-CD19 / CD20 / γδT trispecific antibody

[0370] This experiment used the Biacore biomolecular interaction analyzer and surface plasmon resonance (SPR) technology to determine the affinity kinetics of the interaction between the anti-CD19 / CD20 / γδT trispecific antibody and human CD19 (Kactus, Cat#CD1-HM119), γδTCR antigen (recombinant human γ9δ2TCR protein prepared using the method in Example 1), and CD20 antigen (CD20-VLP) proteins.

[0371] Affinity kinetics of the interaction between anti-CD19 / CD20 / γδT trispecific antibodies and human CD19 / γδT antigens were determined using a Protein A biosensor chip (Cityva, Cat#29-1275-56). The antibody at a specific concentration was prepared as a ligand using HBS-EP+ buffer solution and captured into the Protein A chip's Fc2 (Flow cell 2, Fc2) channel at a flow rate of 10 μL / min for 30 s. A series of concentration gradients of human CD19 (300 nM–4.6875 nM) or γδT (150 nM–2.3475 nM) antigen protein were prepared as analytes using HBS-EP+ buffer solution, serially diluted 2-fold, resulting in 7 concentration points. These were injected into the chip's reference channel Fc1 (Flow cell 1, Fc1) and detection channel Fc2 at a flow rate of 30 μL / min. For human CD19 analytes: binding time 80 s, dissociation time 350 s; for human γδT analytes: binding time 60 s, dissociation time 400 s. Regeneration was finally performed using 10 mM Glycine pH 1.5 (Cytiva, Cat#BR-1003-54). Regeneration conditions were: regeneration time 30 s, flow rate 30 μL / min. The buffer used in the experiment was HBS-EP + 10× buffer solution (Cytiva, Cat.#BR100669) diluted to 1× (pH 7.4) with DIWater.

[0372] Affinity kinetics analysis of the interaction between anti-CD19 / CD20 / γδT trispecific antibodies and human CD20 antigen: Using an SA sensor chip (Cytiva, Cat#BR100531), a specific concentration of WGA protein (Vector Laboratories part no. B-1025) was prepared with HBS-EP+ buffer solution and captured in channels Fc1 and Fc2 of the SA chip at a flow rate of 10 μL / min for a capture time of 30 s. A specific concentration of human CD20-VLP was prepared with HBS-EP+ buffer solution as a ligand and injected into channel Fc2 at a flow rate of 10 μL / min for a capture time of 300 s, with a capture RU value exceeding 2000 RU. WGA exhibits a high affinity for the sugars on the surface of VLPs, effectively capturing CD20-VLPs and immobilizing them on the chip. Monovalent anti-CD19 / CD20 / γδT trispecific antibodies (1000 nM - 15.625 nM) were used as analytes and serially diluted 2-fold to obtain 7 concentration points. These concentration gradients were prepared using HBS-EP+ buffer and flowed through the Fc1 and Fc2 channels of the SA chip at a flow rate of 30 μL / min. The binding time was 90 s, and the dissociation time was 150 s. Finally, regeneration was performed using 10 mM Glycine at pH 1.5. The regeneration conditions were: regeneration time 30 s, flow rate 30 μL / min. The buffer used in the experiment was HBS-EP+ 10× buffer diluted to 1× (pH 7.4) with DIWater.

[0373] Data statistics and analysis: The experimental data were fitted to the Langmuir model using Biacore 8K insight Evaluation Software at a 1:1 scale to obtain the binding parameter Ka, dissociation parameter Kd, and affinity KD values.

[0374] Experimental Results: The affinity dissociation constants of SDP04908 and SDP04909 with human CD19, CD20, or γδT antigens are shown in Table 8 (1:1 binding). The results show that SDP04908 and SDP04909 have similar affinities, and the affinity K for human CD19 is similar. D Value at 10 -9 On the order of M, the affinity with human CD20 is K. D Value at 10 -8 On the order of M, the affinity for human γδT is K. D Value at 10 -10 On the order of M.

[0375] Table 8. Binding affinities of anti-CD19 / CD20 / γδT trispecific antibodies to antigens CD19, CD20, and γδT

[0376] Example 8. Binding of anti-CD19 / CD20 / γδTCR trispecific antibody to human CD19 and CD20 positive cells

[0377] 1. The binding activity of CD19 / CD20γδT antibodies to human CD19 or CD20 single-positive cells was detected using FACS assays. K562-human CD19 and K562-human CD20 cells were obtained by transfecting K562 cells (purchased from the Chinese Academy of Sciences Cell Bank) with lentiviruses expressing human CD19 and CD20, respectively, and then selecting single clones. The binding activity of anti-CD19 / CD20 / γδT antibodies on different cell types was assessed by detecting the fluorescence signal of antibody binding on the cell surface; the intensity of the fluorescence signal was used to evaluate the antibody binding strength. Specifically, serially diluted antibody molecules and control molecules were mixed at 1 x 10⁻⁶ cells / cell. 5 Cells were incubated at 4°C for 1 hour, excess antibody was washed away, and mouse-derived Alexa Flour 647-labeled anti-human Fc antibody (Jackson, Cat#209-605-098) was added. After incubation at 4°C for 30 minutes, excess antibody was washed away, and the cells were resuspended in 200 μL of 2% FBS / PBS buffer. The fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer.

[0378] The results are shown in Figures 2A-2B and Table 9. The binding activity trends of SDP04908 and SDP04909 on CD19 or CD20 single-positive cells are consistent.

[0379] Table 9. Detection of CD19 / CD20 single-positive cell binding activity Note: - indicates no binding activity.

[0380] 2. The binding activity of CD19 / CD20γδT antibodies to monkey CD19 or CD20 single-positive cells was detected using FACS assays. K562-monkey CD19 and K562-monkey CD20 cells were obtained by transfecting K562 cells (purchased from the Chinese Academy of Sciences Cell Bank) with monkey CD19 and CD20 lentiviruses, respectively, and then selecting single clones. The binding activity of anti-CD19 / CD20 / γδT antibodies on different cells was assessed by detecting the fluorescence signal of antibody binding on the cell surface; the intensity of the fluorescence signal was used to evaluate the antibody binding strength. Specifically, serially diluted antibody molecules and control molecules were mixed at 1 x 10⁻⁶ cells / cell. 5Cells were incubated at 4°C for 1 hour, excess antibody was washed away, and mouse-derived Alexa Flour 647-labeled anti-human Fc antibody (Jackson, Cat#209-605-098) was added. After incubation at 4°C for 30 minutes, excess antibody was washed away, and the cells were resuspended in 200 μL of 2% FBS / PBS buffer. The fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer.

[0381] The results are shown in Figures 3A to 3B and Table 10. SDP04908 and SDP04909 can bind well to monkey-derived CD19 and CD20.

[0382] Table 10. Detection of antibody binding activity against monkey CD19 / CD20 cells Note: - indicates no binding activity.

[0383] Example 9. Detection of the killing activity of CD19 / CD20 / γδTCR antibody-mediated γδT cells against tumor cells

[0384] This embodiment uses Bright-Glo TM The luciferase reporter gene assay system was used to evaluate the antibody-mediated killing activity of γδT cells against target cells with different CD19 and CD20 expression levels.

[0385] Daudi and Raji cells naturally highly express CD19 and CD20, WSU-DLCL2 cells express low levels of CD19 and high levels of CD20, and RS4 and RS11 cells express high levels of CD19 and low levels of CD20. All cells were cultured in RPMI 1640 (Gibco, Cat#10491A-01, hereinafter the same) containing 10% inactivated fetal bovine serum. Single clones were obtained after transfecting the four cell types with pLenti-CMV-Luc2-IRES-Neo-WPRE lentivirus. Target cells were digested and resuspended in RPMI 1640 medium with 2% serum, and the density was adjusted to 2 × 10⁶ cells / mL. 4 Cells / mL; then seeded at 50 μL / well in a 96-well plate, and added 50 μL of serially diluted test antibody. Add 50 μL of culture medium to each well. Collect γδT cells, resuspend in RPMI 1640 containing 2% fetal bovine serum, and adjust the cell density to a final E:T ratio of 5:1. Seed at 50 μL / well in the above experimental plate and incubate at 37°C, 5% CO2 for 24 hours. Remove the cell culture plate, centrifuge (400g, 5 min) to collect the cell culture supernatant, and analyze using a Bright-Globe assay. TM The luciferase detection system (Promega, E2650) measures fluorescence levels. Refer to the reagent instruction manual for detailed operation instructions.

[0386] The results, as shown in Figures 4A to 4D and Table 11, indicate that SDP04908 and SDP04909 have strong in vitro killing effects and also have killing effects on cells with low expression of CD19 or CD20.

[0387] Table 11. Killing effect of CD19 / CD20 / γδTCR antibody combined with γδT on cells expressing different antigens Note: - indicates no lethal activity, / indicates not detected.

[0388] Example 10. Validation of the efficacy of CD19 / CD20 / γδTCR antibody in mice with hematologic malignancies

[0389] In this embodiment, NOG mice (female, 6-8 weeks old, provided by Vital River) were injected via tail vein with Daudi-Luci cells (5 × 10⁻⁶). 6 As an animal model, 10 animals were randomly divided into 6 groups (G1-G6) with 10 cells / 100μL / animal. Starting the day after tumor injection, candidate molecules were administered intraperitoneally and γδT cells (1×10⁶ cells / 100μL / animal) were injected via tail vein. 7 Cells / 100 μL / animal, once weekly. Seven days after administration, fluorescence imaging and quantification were performed periodically using the PerkinElmer IVIS Lumina III small animal in vivo optical imaging system. Specific groupings are as follows:

[0390] G1: Vehicle

[0391] G2: γδT cells + PBS

[0392] G3: γδT cells + SDP04908 (1 mg / kg)

[0393] G4: γδT cells + SDP04908 (5 mg / kg)

[0394] G5: γδT cells + SDP04909 (1 mg / kg)

[0395] G6: γδT cells + SDP04909 (5 mg / kg)

[0396] The results are shown in Table 12 and Figures 5A and 5C. The candidate molecules combined with γδT cells had a more significant tumor-suppressing effect than γδT cells alone. After 29 days of administration, the fluorescence signals of the SDP04908 and SDP04909 groups were significantly reduced, indicating that the triple anti-tumor molecules have a good anti-tumor effect.

[0397] Table 12. Antitumor activity of candidate molecules in the Daudi hematologic malignancy model Note: ** represents vs G2, P<0.01; **** represents vs G2, P<0.0001.

[0398] Example 11. Detection of the efficacy of CD19 / CD20 / γδTCR antibody in mouse tumors.

[0399] In this embodiment, NOG mice (female, 6-8 weeks old, provided by Vital River) were subcutaneously inoculated with WSU-DLCL2 cells (1×10⁶ cells per mouse) on the right side of their back. 7 Using cells / 100μL + 100μL Matrigel as an animal model, 8 animals were randomly divided into 6 groups (G1-G6). Starting the day after tumor injection, candidate molecules were administered intraperitoneally (once a week) and γδT cells (1×10⁻⁶) were injected via tail vein. 7 Cells / 100μL / animal, twice a week), tumor volume was measured and recorded periodically using calipers 7 days after administration. The calculation formula is as follows (the same applies below):

[0400] Calculate tumor volume (TV) = 1 / 2 × a × b 2 , where a and b represent the long and short diameters of the tumor, respectively;

[0401] Relative tumor proliferation rate T / C% = (T-T0) / (C-C0) × 100;

[0402] Tumor inhibition rate (TGI%) = 1 - T / C%.

[0403] The dosing groups are as follows:

[0404] G1: Vehicle

[0405] G2: γδT cells + PBS

[0406] G3: γδT cells + SDP04908 (1 mg / kg)

[0407] G4: γδT cells + SDP04908 (5 mg / kg)

[0408] G5: γδT cells + SDP04909 (1 mg / kg)

[0409] G6: γδT cells + SDP04909 (5 mg / kg)

[0410] The results are shown in Table 13 and Figure 6A. The combination of SDP04909 at a dose of 5 mg / kg with γδT cells had a more significant tumor-suppressing effect than γδT cells alone.

[0411] Table 13. Antitumor activity of candidate molecules in the WSU-DLCL2 subcutaneous tumor model

[0412] Example 12. Binding of CD19 / CD20 / γδTCR trispecific antibody to Raji cells

[0413] The binding activity of CD19 / CD20γδTCR antibody to Raji cells was detected using FACS assays. The binding activity assay of anti-CD19 / CD20 / γδT antibody SDP11431 on Raji cells was evaluated by detecting the fluorescence signal of antibody binding on the cell surface, and the intensity of the fluorescence signal was used to assess the antibody binding strength. Specifically, serially diluted antibody molecules and control molecules were mixed at 1 x 10⁻⁶ cells / mL. 5 Cells were incubated at 4°C for 1 hour, excess antibody was washed away, and mouse-derived Alexa Flour 647-labeled anti-human Fc antibody (Jackson, Cat#209-605-098) was added. After incubation at 4°C for 30 minutes, excess antibody was washed away, and the cells were resuspended in 200 μL of 2% FBS / PBS buffer. The fluorescence signal on the cell surface was read using a Thermo Attune NxT flow cytometer.

[0414] The results are shown in Figure 7 and Table 14. The binding activity trends of SDP04909 and SDP11431 on Raji cells are consistent.

[0415] Table 14. Detection of Raji cell-binding activity of triple antibodies Note: - indicates no binding activity.

[0416] Example 13. Detection of the killing activity of CD19 / CD20 / γδTCR antibody-mediated γδT cells against Raji cells.

[0417] This embodiment uses Bright-Glo TM The luciferase reporter gene assay system was used to evaluate the antibody-mediated killing activity of γδT cells against Raji cells.

[0418] Raji cells naturally overexpress CD19 and CD20. The cells were cultured in RPMI 1640 (Gibco, Cat#10491A-01, hereinafter the same) containing 10% inactivated fetal bovine serum. Four cell lines were transfected with pLenti-CMV-Luc2-IRES-Neo-WPRE lentivirus, and single clones were selected. Target cells were digested and resuspended in RPMI 1640 medium with 2% serum, with the density adjusted to 2 × 10⁶ cells / year. 4Cells / mL; then seeded at 50 μL / well in a 96-well plate, and added 50 μL of serially diluted test antibody. Add 50 μL of culture medium to each well. Collect γδT cells, resuspend in RPMI 1640 containing 2% fetal bovine serum, and adjust the cell density to a final E:T ratio of 5:1. Seed at 50 μL / well in the above experimental plate and incubate at 37°C, 5% CO2 for 24 hours. Remove the cell culture plate, centrifuge (400g, 5 min) to collect the cell culture supernatant, and analyze using a Bright-Globe assay. TM The luciferase detection system (Promega, E2650) measures fluorescence levels. Refer to the reagent instruction manual for detailed operation instructions.

[0419] The results, as shown in Figure 8 and Table 15, indicate that SDP04909 and SDP11431 have a strong killing effect on CD19CD20 double-positive cells Raji.

[0420] Table 15. Killing effect of CD19 / CD20 / γδTCR antibody combined with γδT on cells expressing different antigens (ECG) 50 ,pM) Note: - indicates no lethal activity.

[0421] Example 14: Detection of B cell clearance in PBMCs mediated by CD19 / CD20 / γδTCR antibody

[0422] In this embodiment, FACS was used to detect the proportion of B cells and to calculate the killing effect of SDP11431 on B cells.

[0423] Three different donor PBMCs (SaiLi Bio, as shown in Table 16) were selected, and the cell density was adjusted to 2 × 10⁶ cells using RPMI 1640 containing 2% fetal bovine serum. 4 Cells / mL; then seeded at 100 μL / well in 96-well plates, and 100 μL of serially diluted test antibody was added. Incubated at 37°C, 5% CO2 for 48 hours. Remove the cell culture plate, centrifuge (400g, 5 min), discard the supernatant, resuspend in 2% FBS / PBS buffer containing anti-CD79B-FITC antibody, incubate at 4°C for 1 hour, wash away excess antibody, resuspend in 150 μL of 2% FBS / PBS buffer, and read the fluorescence signal on the cell surface using a Thermo Attune NxT flow cytometer.

[0424] The results, as shown in Figures 9A-9C, indicate that B cell depletion capacity is related to the proportion of γδT in different donor cells. SDP04908 and SDP11431 showed significant B cell clearance capacity in the PBMC killing model, providing a basis for developing indications such as SLE.

[0425] Table 16. Proportions of CD3, CD19 and γδT from different donors

Claims

1. A CD19 / CD20 / gammadelta TCR binding protein comprising a gammadelta T cell receptor (gammadelta TCR) binding domain, a CD19 binding domain, and a CD20 binding domain; wherein, The γδTCR binding domain comprises a single variable immunoglobulin domain, which includes: CDR1, CDR2, and CDR3 in any of the amino acid sequences shown in SEQ ID NO:28, 61, 69-71, wherein the CDRs are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system; or CDR1, CDR2, and CDR3 as shown in SEQ ID NO:13, 14, and 15, respectively.

2. The CD19 / CD20 / γδTCR binding protein of claim 1, wherein, The CD19 binding domain comprises a heavy chain variable region (VH1) and a light chain variable region (VL1), wherein: The VH1 comprises HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequence of SEQ ID NO:22, and the VL1 comprises LCDR1, LCDR2, and LCDR3 as shown in the amino acid sequence of SEQ ID NO:23; wherein the CDRs are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system; or, The VH1 includes HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:1-3, and the VL1 includes LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:4-6.

3. The CD19 / CD20 / γδTCR binding protein of claim 1 or 2, wherein, The CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein: The VH2 comprises HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequence of SEQ ID NO:24, and the VL2 comprises LCDR1, LCDR2, and LCDR3 as shown in the amino acid sequence of SEQ ID NO:25; wherein the CDRs are defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system; or, The VH2 comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:7-9, and the VL2 comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:10-12.

4. The CD19 / CD20 / γδTCR binding protein of claim 1 or 2, wherein, The CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein: The VH2 contains HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequence of SEQ ID NO:26, and the VL2 contains LCDR1, LCDR2, and LCDR3 as shown in the amino acid sequence of SEQ ID NO:27; or, The VH2 includes HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:16-18, and the VL2 includes LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:19-21, respectively; The CDR is defined according to the Kabat, IMGT, Chothia, AbM, or Contact numbering system.

5. The CD19 / CD20 / γδTCR binding protein of any one of claims 1-4, wherein, The γδTCR binding domain, the CD19 binding domain, and / or the CD20 binding domain are humanized.

6. The CD19 / CD20 / γδTCR binding protein of any one of claims 1-5, wherein, The γδTCR binding domain comprises or has at least 80%, preferably at least 90%, identity with any one of SEQ ID NO: 28, 61 and 69-71.

7. The CD19 / CD20 / γδTCR binding protein of any one of claims 1-6, wherein, The CD19 binding domain comprises a heavy chain variable region (VH1) and a light chain variable region (VL1), wherein: The VH1 contains an amino acid sequence as shown in SEQ ID NO:22 or having at least 80%, preferably at least 90%, identical to it, and the VL1 contains an amino acid sequence as shown in SEQ ID NO:23 or having at least 80%, preferably at least 90%, identical to it.

8. The CD19 / CD20 / γδTCR binding protein of any one of claims 1-3 and 5-7, wherein, The CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein: The VH2 comprises an amino acid sequence as shown in SEQ ID NO:24 or having at least 80%, preferably at least 90%, identical to it, and the VL2 comprises an amino acid sequence as shown in SEQ ID NO:25 or having at least 80%, preferably at least 90%, identical to it.

9. The CD19 / CD20 / γδTCR binding protein of any one of claims 1-2 and 4-7, wherein, The CD20 binding domain comprises a heavy chain variable region (VH2) and a light chain variable region (VL2), wherein: The VH2 comprises an amino acid sequence as shown in SEQ ID NO:26 or having at least 80%, preferably at least 90%, identical to it, and the VL2 comprises an amino acid sequence as shown in SEQ ID NO:27 or having at least 80%, preferably at least 90%, identical to it.

10. The CD19 / CD20 / γδTCR binding protein of any one of claims 1-9, further comprising an immunoglobulin Fc region, wherein, The immunoglobulin Fc region is derived from human IgG1, human IgG2, human IgG3 or human IgG4; Preferably, the Fc region is selected from any of the following Fc regions: (1) The Fc region of human IgG1 with reduced antibody-dependent cell-mediated cytotoxicity (ADCC) and / or reduced complement-dependent cytotoxicity (CDC). (2) The Fc region of human IgG1 containing at least one mutation as shown below: L234A or L234F, L235A or L235E, and D265S, said mutations as defined according to the EU numbering system; and (3) An Fc region containing an amino acid sequence as shown in any one of SEQ ID NO:39-40 and 74-75 or having at least 80% or at least 90% identity with it.

11. The CD19 / CD20 / γδTCR binding protein of claim 10, wherein, The Fc region comprises a first subunit and a second subunit; Preferably, the first and second subunits of the Fc region contain a knock-into-hole mutation; More preferably, The second subunit of the Fc region contains a mutation at position 366, and the first subunit contains a mutation selected from positions 366, 368, or 407, or any combination thereof. The second subunit of the Fc region contains a mutation at position 354 or 356, and the first subunit contains a mutation at position 349; or The second subunit of the Fc region contains a mutation at position 354 or 356, and the first subunit contains a mutation at position 349, 366, 368 or 407, or any combination thereof. More preferably, The second subunit of the Fc region contains the 366W mutation, and the first subunit contains a mutation selected from 366S, 368A and 407V or any combination thereof. The second subunit of the Fc region contains a 354C or 356C mutation, and the first subunit contains a 349C mutation; or The second subunit of the Fc region contains the 354C / 366W mutation, and the first subunit contains the 349C / 366S / 368A / 407V mutation.

12. The CD19 / CD20 / γδTCR binding protein of any one of claims 1-11, wherein, The CD19 / CD20 / γδTCR binding protein is an anti-CD19 / CD20 / γδTCR antibody or an antigen-binding fragment.

13. A CD19 / CD20 / γδTCR binding protein comprising a CD19 binding domain, a CD20 binding domain, and a γδTCR binding domain; wherein, The γδTCR binding domain includes an immunoglobulin variable domain, the CD19 binding domain includes a heavy chain variable region (VH1) and a light chain variable region (VL1), and the CD20 binding domain includes a heavy chain variable region (VH2) and a light chain variable region (VL2). Preferably, the CD19 / CD20 / γδTCR binding protein comprises a first heavy chain, a first light chain, a second heavy chain, and a second light chain, wherein, from the N-terminus to the C-terminus, the first heavy chain, the first light chain, the second heavy chain, and the second light chain have the following structure: (1) The first heavy chain includes [VH1]-[connector 1]-[CH1]-[connector 2]-[Fc1], The first light chain includes [VL1]-[connector 3]-[CL], The second heavy chain includes [immunoglobulin variable domain]-[linker 4]-[VH2]-[linker 5]-[CH1]-[linker 6]-[Fc2], The second light chain includes [VL2]-[connector 7]-[CL]; or, (2) The first heavy chain includes [VH1]-[connector 1]-[CH1]-[connector 2]-[Fc2], The first light chain includes [VL1]-[connector 3]-[CL], The second heavy chain includes [immunoglobulin variable domain]-[linker 4]-[VH2]-[linker 5]-[CH1]-[linker 6]-[Fc1], The second light chain includes [VL2]-[connector 7]-[CL]; or, (3) The first heavy chain includes [VH1]-[connector 8]-[Obscurin-O chain]-[connector 9]-[Fc1], The first light chain includes [VL1]-[connector 10]-[Titin-T chain], The second heavy chain includes [immunoglobulin variable domain]-[linker 11]-[VH2]-[linker 12]-[CH1]-[linker 13]-[Fc2], The second light chain includes [VL2]-[connector 14]-[CL]; or, (4) The first heavy chain includes [VH1]-[connector 8]-[Obscurin-O chain]-[connector 9]-[Fc2], The first light chain includes [VL1]-[connector 10]-[Titin-T chain], The second heavy chain includes [immunoglobulin variable domain]-[linker 11]-[VH2]-[linker 12]-[CH1]-[linker 13]-[Fc1], The second light chain includes [VL2]-[connector 14]-[CL]; Preferably, the CD19 binding domain, CD20 binding domain, and γδTCR binding domain are independently defined as the CD19 binding domain, CD20 binding domain, and γδTCR binding domain as described in any one of claims 1-12; Preferably, the Obscurin-O chain comprises an amino acid sequence as shown in SEQ ID NO:29 or having at least 80% or 90% identity with it. The Titin-T chain contains an amino acid sequence as shown in SEQ ID NO:30 or having at least 80% or 90% identity with it. The CH1 contains an amino acid sequence as shown in SEQ ID NO:31 or having at least 80% or at least 90% identity with it. The CL contains an amino acid sequence as shown in SEQ ID NO:32 or having at least 80% or at least 90% identity with it; Preferably, Fc1 contains an amino acid sequence as shown in or having at least 80% or 90% identity with SEQ ID NO:39 or 74, and Fc2 contains an amino acid sequence as shown in or having at least 80% or 90% identity with SEQ ID NO:40 or 75. Preferably, the connectors 1-14 are either present or absent independently of each other; connectors 1-3 are preferably absent; connector 4 is preferably G4S or (G4S)2; connectors 5-7 are preferably absent; connectors 8 and 10 are preferably G4S or (G4S)2; connector 11 is preferably G4S or (G4S)2; and connectors 9, 12, and 13-14 are preferably absent.

14. The CD19 / CD20 / γδTCR binding protein according to any one of claims 1-13, comprising a first heavy chain, a first light chain, a second heavy chain, and a second light chain, wherein: (1) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:33 or having at least 80%, preferably at least 90% identity with it. The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80%, preferably at least 90%, identity with it. The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:35 or having at least 80%, preferably at least 90%, identity with it, and The second light chain comprises an amino acid sequence as shown in SEQ ID NO:36 or having at least 80%, preferably at least 90% identity with it; or, (2) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:33 or having at least 80%, preferably at least 90% identity with it. The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80%, preferably at least 90%, identity with it. The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:37 or having at least 80%, preferably at least 90%, identity with it, and The second light chain comprises an amino acid sequence as shown in SEQ ID NO:38 or having at least 80%, preferably at least 90% identity with it; or, (3) The first heavy chain contains an amino acid sequence as shown in SEQ ID NO:55 or having at least 80%, preferably at least 90% identity with it. The first light chain comprises an amino acid sequence as shown in SEQ ID NO:34 or having at least 80%, preferably at least 90%, identity with it. The second heavy chain comprises an amino acid sequence as shown in SEQ ID NO:56 or having at least 80%, preferably at least 90%, identity with it, and The second light chain comprises an amino acid sequence as shown in SEQ ID NO:38 or having at least 80%, preferably at least 90%, of the same identity.

15. A polynucleotide encoding the CD19 / CD20 / γδTCR binding protein according to any one of claims 1-14; Preferably, the polynucleotide is DNA or RNA.

16. A vector comprising the polynucleotide of claim 15.

17. A host cell containing or expressing the polynucleotide of claim 15 or the vector of claim 16.

18. A method for preparing CD19 / CD20 / γδTCR binding protein, including: The expression of the polynucleotide of claim 15 or the vector of claim 16 in a host cell, and the isolation and expression of the CD19 / CD20 / γδTCR binding protein from the host cell; Optionally, the process further includes a step of purifying the CD19 / CD20 / γδTCR binding protein.

19. A pharmaceutical composition comprising the CD19 / CD20 / γδTCR binding protein of any one of claims 1-14, the polynucleotide of claim 15, or the carrier of claim 16; and optionally one or more pharmaceutically acceptable excipients, diluents, or carriers.

20. A pharmaceutical combination comprising: The CD19 / CD20 / γδTCR binding protein and T cells according to any one of claims 1-14, wherein the T cells are preferably γδT cells.

21. A method of treating or preventing disease, comprising administering to a subject in need the CD19 / CD20 / γδTCR binding protein of any one of claims 1-14, the polynucleotide of claim 15, the carrier of claim 16, the pharmaceutical composition of claim 19, or the pharmaceutical combination of claim 20; The disease is preferably a B-cell tumor, more preferably a lymphoma, and even more preferably a B-cell lymphoma; The disease is preferably a CD19-positive and CD20-positive tumor, more preferably a CD19-positive and CD20-positive B-cell tumor.

22. The uses of T cells in the preparation of drugs for treating diseases, including: Use of the CD19 / CD20 / γδTCR binding protein of any one of claims 1-14, the polynucleotide of claim 15, the carrier of claim 16, or the pharmaceutical composition of claim 19 in the preparation of a medicament for treating a disease; Preferably, the CD19 / CD20 / γδTCR binding protein, polynucleotide, carrier, or pharmaceutical composition is used in combination with T cells, wherein the T cells are preferably γδT cells; The disease is preferably a B-cell tumor, more preferably a lymphoma, and even more preferably a B-cell lymphoma; The disease is preferably a CD19-positive and CD20-positive tumor, more preferably a CD19-positive and CD20-positive B-cell tumor.